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ABSTRACT  
 
The nuclear hormone receptors, ERα and ERβ, are known to regulate the transcriptional 
response programs of their target cells, including breast cancer cells. However, their comparative 
abilities to localize at chromatin binding sites across the genome, the recruitment of major 
coregulators such as SRC3 and RIP140 by the ERs, and the association of ERs with other 
transcription factors and chromatin remodeling factors is incompletely understood. Therefore, in 
this report, we have used both chromatin immunoprecipitation (ChIP) on microarray (ChIP-chip) 
and ChIP sequencing (ChIP-seq) approaches in breast cancer cells containing three different 
complements of ERs (ERα alone, ERβ alone, or ERα + ERβ) treated with estradiol to define the 
cartography of chromatin binding sites for ERα, ERβ, and the coregulators SRC3 and RIP140. 
We found that ERα and ERβ bind to a similar, large number of sites in breast cancer cells 
containing only one ER subtype, but the two ERs appear to restrict each others chromatin 
binding and occupy fewer sites in cells containing both ERα and ERβ. We also observed that 
there are differences in terms of enriched motifs in ERα and ERβ binding sites, with ERα 
binding sites enriched in GATA and FOXA1 motifs, but ERβ sites being preferentially enriched 
in E2F motifs. In addition, in cells containing both ERα and ERβ, ERα appears to displace ERβ 
so that ERβ binds to sites substantially less enriched in estrogen response element (ERE) 
sequence motifs.  
Gene chip microarray transcriptional profiling and gene ontology analysis delineated a core 
set of genes that correlate with ERα proliferative and ERβ anti-proliferative effects in breast 
cancer cells. ERβ activation by estradiol was associated with the inhibition of genes associated 
with cell proliferation and the up-regulation of pro-apoptotic genes and genes responding to 
DNA damage, whereas ERα activation was associated with the downregulation of pro-apoptotic 
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genes and genes repressing transcription. Analysis of chromatin binding of SRC3 and RIP140 by 
ChIP-seq revealed that these coregulators are recruited preferentially to ER binding sites of 
estrogen-induced genes, whereas they are seldom recruited to ER binding sites of hormone-
repressed genes, indicating that the SRC3-RIP140 complex is likely to be playing a central role 
in the induction of ER targeted genes. Our findings suggest an integrated model in which the 
actions of cofactors such as FOXA1, GATA3, and E2F enforce the selectivity and range of ERα 
and ERβ binding and gene regulatory actions, with the coregulators SRC3 and RIP140 
preferentially supporting the stimulatory actions of both receptors on gene expression. 
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CHAPTER 1 
INTRODUCTION 
1.1 ESTROGEN RECEPTORS (ERs) 
Estrogens play key roles in many aspects of reproductive physiology, development, and 
metabolism, and they are also involved in several disease states, including breast and 
endometrial cancers [1, 2]. The effects of estrogens are mediated through two estrogen receptors, 
estrogen receptor alpha (ERα)and beta (ERβ), that function as ligand-modulated transcription 
factors, up- and down-regulating gene expression in a target tissue-selective manner [3, 4]. The 
presence of ERα in breast cancer cells and in various tissues is associated with enhanced 
proliferation in response to estrogens, whereas several studies have implicated ERβ as exerting 
antiproliferative effects [5-9].  
ERα and ERβ are members of the nuclear receptor superfamily, representing a class of 
signal-activated DNA-binding transcription factors that respond to small molecule ligands, such 
as estrogens. Both ERα and ERβ each contain a ligand-binding domain (LBD), a DNA-binding 
domain (DBD), and two activation domains (AF-1 and AF-2). ERα and ERβ are highly 
homologous in their DNA-binding domains (97% identity), but they are quite different in their 
ligand-binding domains (56% identity) and transcriptional activation function-1 (18% identity) 
domains. The differences in their ligand-binding domains allow the two ER subtypes to bind 
certain ligands with high selectivity, for one or the other ER subtype [10-13]. Thus, in cells 
containing both ERs, it is possible to activate either receptor selectively by using subtype-
selective ligands. Also, due to the differences in the AF-1 domains between the two estrogen 
receptors, ERα and ERβ can exert receptor-specific function by interacting with and recruiting 
different proteins.  
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1.2 MOLECULAR MECHANISMS OF ESTROGEN ACTION 
Estrogen acts through its receptors, ERα and ERβ, to control patterns of gene expression in 
target tissues. It is now well documented that ERα and ERβ can exist in cells as homodimers 
when present alone, and additionally as heterodimers when present together. The ERs dimers are 
responsible for the regulation of transcriptional activation.  
There are several distinct pathways by which estrogen can mediate the biological processes, 
namely, classic ER action or non-genomic mechanisms. In the classic estrogen actions, ERs 
function as dimers and bind to regulatory sites on the chromatin where they recruit a variety of 
coregulators, histone-modifying enzymes, and other factors to up or downregulate the 
transcription of hundreds of genes that markedly influence cell phenotype. Some of the 
chromatin binding sites to which the ERs bind are known as estrogen-response elements (EREs). 
The consensus ERE consists of a 13bp sequence, GGTCAnnnTGACC. However, recent 
genome-wide studies on ERs chromatin sites [14-17] showed that many of ER binding sites do 
not contain the consensus ERE motif. In addition to direct DNA binding, ERs can also mediate 
estrogen-signaling by “tethering” onto other transcription factor complexes such as stimulating 
protein 1 (SP1) [18], and activating protein 1 (AP1) [19]. Estrogen can also exert its effects 
through non-genomic mechanisms where it binds to ERs localized on the plasma membrane and 
initiates extranuclear signaling through activation of kinase cascades [20, 21]. 
 
1.3 ROLES OF ERα AND ERβ IN BREAST CANCER 
Estrogen has been implicated in the promotion and growth of breast cancer. Although ERα is 
usually the predominant ER in breast tumors and is currently used as a indicator for the 
responsiveness to endocrine therapies, most human breast tumors also coexpress both ERs, with 
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the level of ERβ covering a broad range [22-24]. It is well documented that ERα in breast cancer 
cells is associated with enhanced proliferation in response to estrogens; however, the effects of 
ERβ in breast cancer are less clear, although in vitro studies have indicated that ERβ can 
modulate the proliferation and invasion of breast cancer cells [3, 25]. The modulating ability of 
ERβ on ERα and its subsequent loss in a majority of breast tumors [26, 27] suggest that ERβ can 
be a tumor suppressor gene.  
 
1.4 EXPRESSION PROFILING OF ER ACTION 
With the introduction of the DNA microarray platform, it has become feasible to 
simultaneously query the expression of thousands of genes with great precision. Our lab and 
other have taken advantage of this technology to comprehensively study the estrogen-regulated 
gene expression profiles in breast cancer and osteosarcoma cell lines expressing either ERα or 
ERβ [5, 9, 28, 29]. These studies have provided us with a system-wide view of ERs actions on its 
target genes and have also given us an unprecedented view of the transcriptome dynamics in 
response to E2 and selective estrogen receptor modulators (SERMs). Although both ERα and 
ERβ have been shown to be able to heterodimerize when present in the same cell, the impact of 
heterodimerization on gene regulation is still unclear. Hence, our lab had preformed several gene 
expression studies aimed at studying the interplay between ERα and ERβ, and characterizing the 
role of ERβ in influencing the transcriptional activity of ERα. To access the modulatory effects 
of ERβ, we used adenovirus-mediated gene delivery method to express ERβ in MCF-7 (ERα 
only cells) breast cancer cells to create cells that can express both ERa and ERb [3]. This allowed 
us to examine ERα-mediated transcription (in ERα only cells) and the modulating effects of 
ERβ on ERα-mediated transcription (in ERα and ERβ expressing cells). Our studies indicate 
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that the co-expression of ERβ with ERα significantly impacted, both in an enhancing and a 
suppressing fashion, the E2-induced transcriptional response by ERα. Of the genes modulated by 
ERβ, the greatest numbers were associated with transcription factors and signal transduction 
pathways [3]. We observed from our expression data that ERβ regulated multiple components in 
the TGFβ, SDF1, and semaphorin pathways, which may contribute, at least in part, to the anti-
proliferativeoh well effects observed when ERβ is present in the cells. In addition, our data 
identified a subclass of E2-regulated genes that responds to E2 stimulation only in the presence 
of ERβ. This raises the possibility that the regulatory regions of these genes contain sequences 
which bias for the recruitment of ERβ but not ERα. A second possibility might be due to the 
different cofactors recruited by either ERα or ERβ complexes which enable the ER complexes to 
access different chromatin regions. Our findings from the above study exemplify the complex 
relationship between ERα and ERβ. However, the study was not able to give a complete picture 
of transcription regulation by the ERs as there was no comparison of ERβ-mediated transcription 
regulation in ERβ-only expressing cells and the expression profiling was also done on gene 
expression arrays (Affymetrix U133A), which contains only half of the current known genes 
(~36 thousands genes are known currently).  
Therefore, in order to completely understand the interplay between ERα and ERβ in breast 
cancer cells, new generation of gene expression chips from Affymetrix or Illumina should be 
used to study ERα- and ERβ-mediated transcription regulation on cells expressing ERα-alone, 
ERβ-alone, and ERα and ERβ. 
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1.5 GENOME-WIDE ANALYSIS OF ERα AND ERβ BINDING SITES 
At the chromatin level, ERα and ERβ interact either via direct binding to regulatory regions 
encoded with EREs or via indirect binding by tethering to other transcription factors such as 
AP1, SP1, and NF-κB. Owing to technological limitations, the mechanisms of ERs chromatin 
binding have been studied only on a small number of endogenous target promoters [30, 31].  
However, a number of recent studies have examined the binding of ERα and ERβ in a less 
biased way, using the powerful combination of chromatin immunoprecipitation (ChIP) coupled 
with either DNA microarrays (ChIP-chip) or DNA sequencing (ChIP-seq) [14-17, 32, 33]. These 
genome-wide ER chromatin binding studies have provided several novel insights into ER 
chromatin binding events. First, the chromatin sites bound by ERα are located at great distances 
(often >100 kilobase pairs) from the promoters of the nearest genes. These unexpected locations 
of ER binding sites relative to gene transcription start sites (TSS) pose a new challenge to 
studying ER mechanism, as we can no longer assume that ERs occupying binding sites located in 
the promoter region will be dictating the transcription of the particular gene. Second, long-range 
activation by liganded ERα bound to distal enhancers was validated by Chromatin Conformation 
Capture (3C) approaches [34]. The 3C study indicated that ERα can regulate genes at great 
distances through a looping mechanism. These studies have provided a genome-wide view of the 
diversity and distribution of ERs binding that was lacking in previous studies. Unfortunately, 
most of these studies examined only ERα binding, with the exception of three studies done by us 
and others [17, 32, 33], that examined ERβ binding sites by ChIP-chip. However, the 
examination of ERβ binding sites by the three studies was not as thorough as the studies done on 
ERα, as either only selected sites in the genome were used (custom-designed arrays [32], only 
selected chromosomes were studied [17], or only one cell-type was used [17, 33] (cells 
 6
expressing ERα and ERβ, but no examination of ERβ binding sites in cells expressing ERβ 
alone). Clearly, additional studies are needed to examine the characteristics of ERβ binding sites 
throughout the whole genome and to investigate ERα and ERβ collaboration and/or competition 
for ER binding sites. 
Deciphering the transcription interplay between ERα and ERβ at chromatin binding sites is 
critical to the elucidation of the mechanism of estrogen-related gene expression in breast cancer. 
Interpolating high-throughput gene expression profiling studies with the growing body of 
genome-wide ERs chromatin binding datasets will enable us to further understand the diverse 
actions of estrogen in breast cancer growth and offer potential new opportunities for therapeutic 
intervention.  
 
1.6 RECRUITMENT OF COREGULATORS TO ER BINDING SITES 
ER-mediated transcription regulation is a complex process involving several steps. Upon 
activation by its ligands, ERα and ERβ will undergo a conformation change which enhances ER 
dimerization and subsequent binding to the regulatory regions of its target genes. Once bound on 
chromatin, the activated ERs recruit the coregulators to form a multiprotein complex that 
activates the general transcriptional machinery and increases or reduces the expression of target 
genes [35, 36]. The coregulators recruited by ERs can be broadly divided into coactivators and 
corepressors. Coactivators are recruited by ERs to enhance transcriptional activation of target 
genes, whereas corepressors are recruited by ERs to silence gene activity. Recent evidence 
indicates that the coregulators assist ERs in regulating transcription by (i) modifying histones 
and (ii) mediating the interactions with the basal transcription apparatus [37, 38]. The modified 
chromatin allows other DNA-bound transcription factors to be subsequently recruited. 
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Consequently, a large array of transcription factors and enzymatic activities converge at the ER 
binding sites in a temporal manner and set the level of gene activation or repression by ERs. 
Coactivators such as Swi/Snf, CBP/p300, p160/SRC and corepressors such as N-CoR and SMRT 
have been shown to be relevant for ERs activity [35]. Crystallographic structures of unliganded 
and agonist-bound ligand binding domains (AF-2 region) of several nuclear receptors (including 
ER) revealed that the AF-2 region undergoes a ligand-dependent conformation change which 
permits the formation of a surface that facilitates coregulator interaction with the nuclear 
receptors [39].  
Given the intimate functional relationships between ER and its coregulators in transcriptional 
regulation, we can conceivably elucidate ER-mediated transcription regulation by examining ER 
chromatin binding coupled with the recruitment of coregulators. This will enable us to get a 
clearer picture of the cartographies of ER chromatin sites. We would be able to separate ER 
binding sites into sites that can impact transcriptional regulatory control and redundant ER 
binding sites in the genome. Knowing ER sites that are exerting transcriptional regulatory control 
will allow us to identify ER target genes.  
 
1.7 AIMS OF THE THESIS RESEARCH 
Intense efforts have been made in the past decades toward the study of ERs in breast cancer 
since estrogens are implicated in the development of breast cancer. As transcription factors, the 
biology of ERα and ERβ in breast cancer can be studied by characterizing their transcriptional 
regulatory impact. This can be done by investigating (i) the chromatin localization of ERα and 
ERβ, (ii) the co-recruitment of coregulators to ER binding sites, and (iii) the interplay between 
ERα and ERβ at the gene expression level. While tangible progress has been made regarding ER 
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functions, they only permit tentative extrapolation when ERs functions are considered in the 
genome-wide context. This is because the biochemical and molecular assays routinely used study 
only one gene at a time. However, in recent years, with the completion of the sequence of the 
human genome and the advent of high-throughput technologies, the field is aptly poised to 
explore ERs functions in breast cancer in a genome-wide, unbiased manner. The main objective 
of this thesis is to comprehensively analyze the genomic targets of ERs actions. We will employ 
genome-wide approaches such as DNA microarrays for global gene expression characterization, 
and ChIP-chip and ChIP-seq assays for protein-chromatin interaction. 
In Chapter 3, we explore the genome-wide chromatin binding sites of ERα and ERβ by ChIP-
chip. Our ER binding site studies showed that there is substantial overlap in ERα and ERβ 
chromatin binding sites when they are present alone in cells, but that many fewer sites are shared 
when both ERs are present together. Although each ER subtype restricts the binding site 
occupancy of the other subtype, overall, ERα appears to dominate the binding of ERβ. We 
showed that the binding site regions of both ERα and ERβ are enriched in estrogen response 
element (ERE) sequence motifs, but when both ERs are present together in the same cell, ERβ 
appears to be displaced by ERα so that it binds to sites substantially less enriched in EREs. 
Chapter 3 highlights the interplay between ERα and ERβ in selecting and competing for 
chromatin binding sites in breast cancer cells. 
In Chapter 4, we aim to understand ERα- and ERβ-mediated transcriptional programs in 
breast cancer by (i) mapping the localization of ERα and ERβ and the recruitment of coregulators 
by ERs to the chromatin and (ii) the subsequent gene regulation by ERs and the coregulators. To 
this end, we employed ChIP-seq technique to map genomic landscape of both ERα and ERβ, and 
the coregulators SRC3 and RIP140 in breast cancer cells. Next, gene expression microarray 
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analyses were carried out to investigate the gene regulatory effects of ERα and ERβ in breast 
cancer cells. Finally, by correlating the global cartographies of ERα, ERβ, SRC3, and RIP140 
with the results of the gene expression microarray analyses, we present evidence of ERs direct 
target genes that may contribute to the ERα proliferative and the ERβ anti-proliferative nature of 
these receptors in breast cancer cells. 
Both Chapter 3 and Chapter 4 highlight the power of genome-wide approaches in examining 
ERs functions. It allows for the generation of massive, unbiased data that can provide valuable 
resources for follow-up studies to further our understanding of ERs actions in breast cancer. 
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CHAPTER 2 
EXPERIMENTAL METHODS AND VALIDATION 
2.1 INTRODUCTION 
Advances in the DNA microarray technology have enable scientists to simultaneously query 
the expression of thousands of genes. Researchers can now routinely monitor the genome-wide 
effects of certain treatments, diseases, and developmental stages at the gene expression level. 
However, the regulation of genes is ultimately determined by the binding of signal-regulated 
transcription factors to regulatory sites across the genome and the subsequent recruitment of 
coregulators by the transcription factors to increase or reduce the expression of the target genes. 
Identifying these DNA regulatory sites for the various transcription factors is a fundamental 
question in biology as it can help us understand the specific mechanisms connecting transcription 
factors chromatin binding, followed by coregulators recruitment and subsequent activation or 
repression of the genes. As ERs are considered master regulators in breast cancer cells and with 
ERs belonging to the class of signal-activated DNA-binding transcription factors, many studies 
were conducted to try to map ER binding sites in the genome using the ERE sequence motif [1-
3]. Predicting ERs binding sites by these computational studies have limited resolution as the 
regions queried for ER binding sites are usually near the promoters of genes and therefore are not 
done on a truly genome-wide manner.  
Recently, identification of ERs binding sites directly, in a genome-wide manner, was 
achieved by combining chromatin immunoprecipitation (ChIP) coupled with either DNA 
microarrays (ChIP-chip) or DNA sequencing (ChIP-seq) [4-9]. However, most of the studies 
only examined ERα chromatin binding. Hence, in order to examine the interplay between ERα 
and ERβ, we used adenoviral gene delivery to transduce ERβ expression in ERα-positive MCF-7 
cells, both without and with siRNA directed against ERα. These manipulations generated cells 
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with three complements of ERs, namely cells containing endogenous ERα only, or ERα+ERβ, or 
ERβ only, as previously described [10] (see Figure 2.1). MCF-7 was chosen for our study as the 
cell-line is extensively studied and all genomic mapping of ER binding sites published to date 
have used MCF-7 cells. Although the generation of sub-lines from wild-type MCF-7 may alter 
cellular composition to some degree, they are nevertheless helpful in dissecting ERα and ERβ 
cross-modulation activities.  
We went on to examine the localization of ERα and ERβ, when present together or 
separately, at ER-binding sites in response to different ligand treatments, using ChIP-chip with a 
custom designed tiling microarray. The design of our ChIP-chip array is detailed in Chapter 2.2. 
Chapter 2.3 gives an overview of how we processed the raw ChIP-chip data to determine ER 
binding peaks. We assessed the effects of unliganded and liganded ERs at ER-binding sites, and 
we used the endogenous ligand E2 (dual activation of ERα and ERβ). In addition, to activate only 
ERα or ERβ, we used the novel, non-steroidal subtype-selective ligands PPT (ERα preferential 
activation [11]) and ERB-041 (ERβ preferential activation [12]). Figure 2.2 shows the effect of 
the different ligand treatments. A major aspect of our study not addressed in any of the previous 
ER ChIP-chip studies is the examination of the comparative binding events of ERα and ERβ 
under different ligand treatments and in breast cancer cells containing only one receptor (either 
ERα or ERβ) or both receptors. This allowed us (i) to discover and map the binding sites of ERα 
and ERβ when they are present alone or together and (ii) to study the mechanistic roles of 
unliganded and liganded ER at the transcriptional level. The ER ChIP-chip study is described in 
Chapter 3 and published in [8]. 
With the popularity and reduction in ChIP-seq cost, we switched from a ChIP-chip based 
assay to ChIP-seq assay to examine ERα and ERβ chromatin binding and the recruitment of 
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coregulators SRC3 and RIP140 to the ERs sites (ChIP-seq methodology and enrichment analysis 
are described in Chapter 2.4). The benefit of ChIP-seq is that it allows us to identify ER binding 
sites without bias (custom-designed ChIP-chip array only allows us to examine specific, 
predetermined sites). At the same time, we performed several gene expression profiling studies 
aimed at examining ERα- and ERβ-mediated transcription regulation on cells expressing ERα-
alone, ERβ-alone, and ERα and ERβ (gene expression profiling of ERs action is described in 
Chapter 2.5). The integrative study on ERs chromatin binding, coregulator recruitment, and gene 
expression profiling is described in Chapter 4. 
 
2.2 ER CUSTOM-DESIGNED CHIP-CHIP TILING ARRAY 
In the ERs ChIP-chip studies described herein, we hybridized our genomic target DNA onto 
custom-designed tiling arrays. The custom array was designed by employing the services of 
NimbleGen (http://www.nimblegen.com/). As transcription factor binding has been shown to be 
cell-line specific, care was taken to ensure that the ERs binding sites included in our arrays are 
found in the cell-line of interest, MCF-7 human breast cancer cells. Specifically, a literature 
search was done on recent published ER ChIP-chip studies, and we selected the datasets based 
on two criteria, (i) the cell-line used must be similar to that used in our studies, MCF-7 cells, and 
(ii) the ChIP-chip assays should be done in an unbiased, genome-wide manner. Due to the 
variation in performance between array technologies, protocols, and algorithms in calling 
binding sites [13], most of the current ChIP-chip studies only provide a partial picture of 
genome-wide binding sites. Therefore, we include, in our array, a dataset based on computational 
predicted ERs binding sites in MCF-7 cells. Control sites were also designed into the arrays to 
ensure the quality of our hybridization experiments. These control sites were designed from both 
 15
ERs non-binding chromatin regions and non-mammalian sequences. Our final ChIP-chip array 
tiling thus contains ~77,000 genomic regions consisting of ~61,000 ER-binding sites and 
~16,000 negative/control regions. The ER-binding sites were selected based on (i) published ER 
ChIP-chip data [4] (10,599 sites), (ii) published ER ChIP-pair end ditag (PET) data (1234 sites) 
[5] and (iii) computational predicted ERE sites using an optimized algorithm [14] (37,499 sites). 
The breakdown of the probes regions is shown in Table 2.1. Each array consists of 38,3520 
probes on them, and each probe is approximately 60 base pairs in length. On average, each 
binding site is covered by 5 or more probes, and the probes are tiled at a distance of ~100 base 
pairs from each other within the binding site, as shown in Figure 2.3. Having several probes 
within a binding site (the probes in each binding site is known as a probe set) increases the 
sensitivity of our arrays as we will be relying on the strength of the probe set signal to determine 
whether ER is bound to the site. Our custom-designed tiling array provides coverage of all 
currently known and predicted ER-binding sites across the entire genome in MCF-7 cells. 
 
2.3 ER CHIP-CHIP BINDING SITES PROCESSING STEPS 
Chromatin DNA fragments with an average size of 700bp were immunoprecipitated and 
subsequently amplified using Sigma Whole Genome Amplification Kit. 10ng of amplified DNA 
was used for each ChIP-chip assay. The ER ChIP-chip assays were run as two-color experiments 
with the experimental (ChIP) DNA sample labeled with dyes of a certain color (Cy5) and the 
control (background) DNA sample labeled with another dye of different color (Cy3) according to 
NimbleGen instructions. The two samples are then co-hybridized onto the array using a MAUI 
hybridization unit and scanned. The signal intensities of the samples (experimental and control) 
at each probe are extracted from the scanned images of the arrays. Enrichment at the probe is 
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quantified by probe intensity log2-ratios (Pj), calculated as the base 2 logarithm of the ratio 
between the experimental and control samples. 
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(20 times) randomly permuting the scaled log2-ratio values and searching for peaks. In general, 
for a ChIP-chip experiment, the lower the FDR score, the more likely the peak corresponds to a 
transcription factor binding site (TFBS).  
In order to determine a FDR cutoff value suitable for our ChIP-chip studies, we conducted a 
negative control ChIP-chip experiment in which we immunoprecipitated ERβ in normal MCF-7 
breast cancer cells and subsequently hybridized the samples on the array. Normal MCF-7 cells 
only contain ERα protein, and therefore there should not be any binding sites in this ChIP-chip 
experiment. By using a FDR of cutoff of 0.2, only 17 peaks were called as binding sites out of a 
potential ~77000 binding regions (see Figure 2.5). This is much lower than the accepted error 
rates in current whole genome ChIP-chip experiment. Hence, for our ChIP-chip studies, we used 
a FDR cutoff of less than 0.2 as indicative of ER binding site. 
 
2.4 CHIP-SEQUENCING OF ERα, ERβ, SRC3, AND RIP140 BINDING SITES 
 
The first next-generation sequencing platform was introduced to the research community in 
2006 by the 454 Corporation. The machine could generate around 200 thousands sequencing 
reads at a read length of approximately 100 base pairs (bp). Suddenly, sequencing became much 
cheaper and faster compared to what was possible with Sanger sequencing. Towards the end of 
2006, Illumina introduced the Genome Analyzer (GA) sequencing machine. The sequencing 
capacity of the GA was impressive as it was able to read up to 80 million DNA template clusters 
simultaneously at an average length of 36-50bp [15, 16]. Although the Illumina sequencing 
machine has a much shorter read length than the 454 instrument, it is extremely well suited for 
sequencing ChIP samples. This is because ChIP DNA fragments are short sequences; so, when it 
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is coupled with Illumina massive parallel reading capacity, ChIP DNA libraries can be 
sequenced and the required data generated at an extreme fast rate.  
Our initial study of ERα and ERβ binding sites was done using a custom-designed ChIP-chip 
tiling array. The probes on the tiling array were designed based on known ERα sites, as well as 
other presumed ER binding sites predicted computationally (Chapter 2.2). Thus, the ChIP-chip 
approach was limited to some degree in its use to study ERβ binding, because some ERβ unique 
binding sites might have been missed. In our second study (Chapter 4), we used the increased 
speed of the ChIP-seq method to study, in a genome-wide unbiased manner, the chromatin 
binding of both ERα and ERβ, as well as the recruitment of the coregulators SRC3 and RIP140 
to the ER sites. All our ChIP-seq libraries were sequenced on the Illumina platform. 
The ChIP-seq libraries were prepared following the manufacturer’s protocols. Briefly, 
chromatin DNA fragments with an average size of 700bp were immunoprecipitated. The ends of 
the DNA fragments were converted into phosphorylated blunt ends by T4 DNA polymerase, 
Klenow enzyme, and T4 polynucleotide kinase. Illumina adaptors were subsequently ligated to 
the ChIP DNA fragments. The DNA fragments were subjected to 15 cycles of PCR 
amplification. The fraction of fragments averaging 200bp was selectively cut out from a 2% 
agarose gel and eluted using a Qiagen gel extraction kit. Using the Illumina platform, 36bp 
length tags were sequenced. The raw sequencing image data were processed by the Illumina 
analysis pipeline and mapped uniquely onto the human reference genome (NCBI v36, hg18) 
using ELAND (Efficient Large-scale Alignment of Nucleotide Databases). 
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2.5 PEAK CALLING FOR CHIP-SEQUENCING TAGS 
 
 After mapping the raw sequenced tags to the genome by ELAND, we needed to identify 
the chromatin binding sites. Binding sites are found by looking for ‘peaks’ – regions of 
significant tag enrichment. There are now a large number of peak-calling programs, both public 
and commercial, that were developed for ChIP-seq [17]. We selected CCAT [18], which was 
developed at Genome Institute of Singapore for peak calling. In addition to sequencing the ChIP 
library for our proteins of interest (ERα, ERβ, SRC3, and RIP140), we also sequenced negative 
control libraries. Negative control libraries, which are also known as Input libraries, are 
generated by sequencing ‘input DNA’ (non-ChIP genomic DNA). As several batches of cells 
were thawed and used to generate the ERα, ERβ, SRC3, and RIP140 ChIP libraries, an Input 
control library was also generated for each batch of cells. This is done to control for cell batch 
variations. CCAT requires both the ChIP library and Input library for peak calling. Based on the 
comparison of the ChIP library and the Input library, CCAT will estimate the confidence of the 
peaks called (quantified by False Discovery Rate (FDR)). For comparison, besides using the 
corresponding Input library to estimate the confidence of the peaks called by CCAT for each 
ChIP library, we also used the other Input libraries. To our surprise, we found that the number of 
peaks called for each ChIP library differed significantly (~6000 to 90000 binding sites between 
different Input libraries) when using different Input libraries. For example, Table 2.2 shows the 
number of peaks called by CCAT for ERβ [β cells] ChIP library across different Input libraries 
(Input_2 is the corresponding Input library generated from the same batch of cells as ERβ [β 
cells] ChIP). The differences in number of peaks called might be caused by cell batch variations 
since the Input libraries were generated from different batch of cells or caused by CCAT peak 
calling algorithm. Upon closer inspection of CCAT results, we noticed that CCAT was using 
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discrete FDR values. For example, the FDR value for peaks in ERβ [β cells] library jumped from 
FDR of 0.055 to FDR 0.09 (see Table 2.3) when the FDR was sorted in ascending order. Hence, 
by using a certain FDR as cutoff, the number of peaks called for a particular ChIP library can be 
different when using different Input libraries, as the FDR values are discrete and not continuous.  
To further confirm that the problem is specifically for CCAT, we used another peak calling 
program, MACS (Model-based Analysis of ChIP-sequencing) [19]. MACS is one of the most 
popular peak calling programs currently used by the ChIP-seq community. As shown in Table 
2.4 (using default MACS cutoff), the number of peaks for ERβ [β cells] is very similar across the 
different Input libraries. This confirms that the variation in the number of peaks across different 
Input libraries (Table 2.2) is caused by the CCAT algorithm which uses discrete FDR values. 
Hence, identification of enriched sites in our sequenced ChIP tags (Chapter 4) was performed 
using MACS software by comparing each ChIP library to the corresponding Input library as a 
control. We defined binding peaks as those above the p-value cutoff of 6e-7 and FDR rate of 
0.01. 
 
2.6 TRANSCRIPTIONAL PROFILING OF ERα AND ERβ ACTIONS 
 
As the ER status in breast tumors is an important prognostic factor of response to endocrine 
therapies, there is much interest in understanding ER-targeted genes. The introduction of DNA 
microarray technology has enable researchers to examine the expression of thousands of genes. 
Both Affymetrix GeneChip and Illumina BeadChip are popular choices because of the large 
number of probes on the arrays and the well-annotated sequences. In addition, many tools have 
been developed for the analysis of the data generated from GeneChip and BeadChip. 
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We performed several gene expression profiling studies, using Affymetrix GeneChIP U133 
plus 2.0, aimed at dissecting ERα- and ERβ-mediated transcription regulation in cells expressing 
ERα-alone, ERβ-alone, and ERα and ERβ together. Total RNA was used to generate cRNA, 
which was labeled with biotin according to techniques recommended by Affymetrix. The biotin-
labeled cRNA was then hybridized to Affymetrix U133 plus 2.0 GeneChips, which contain 
oligonucleotide probe sets for over 47000 transcripts. After washing, the chips were scanned and 
analyzed using Affymetrix processing software. CEL files were processed using GeneSpring GX 
11.0 software (Agilent) to obtain fold-change and p-value (with Benjamini and Hochberg 
multiple test correction) for each gene and for each treatment relative to the vehicle control. We 
considered genes with fold-change > 1.5 and p-value < 0.05 as differential expressed.  
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Table 2.2. Number of peaks called by CCAT for ERβ [β cells] library. 
Input Library No of peaks 
Input_1 240709 
Input_2 150955 
Input_3 190336 
Input_4 210495 
 
Four Input libraries from different batches of cells were used as control by CCAT. (Input_2 is 
generated from the same batch of cells used for ERβ [β cells] ChIP) 
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Table 2.3. FDR values of the peaks called by CCAT for ERβ [β cells] library (control is 
Input_2). 
 
Chromosome Peak location local FDR (ascending order) 
chr10 109546445 0.055 
chr20 34647485 0.055 
chr10 119866655 0.055 
chr13 35186545 0.055 
chr5 29416435 0.055 
chr7 1928775 0.055 
chr13 112151625 0.055 
chr2 132743255 0.09 
chr3 63833095 0.09 
chr20 48720555 0.09 
chr5 127256665 0.09 
chr2 212093375 0.09 
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Table 2.4. Number of peaks called by MACS for ERβ [β cells] library. 
Input Library No of peaks 
Input_1 84300 
Input_2 75547 
Input_3 86658 
Input_4 82705 
 
Four Input libraries from different batches of cells were used as control by MACS. (Input_2 is 
generated from the same batch of cells used for ERβ [β cells] ChIP) 
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Figure 2.1. MCF-7 cells were infected with control β-galactosidase adenovirus or ERβ-
containing adenovirus to generate cells containing ERα-only and ERα+ERβ, respectively. Cells 
containing ERβ-only were generated by the subsequent knockdown of ERαby siRNA 
transfection of cells containing ERα+ERβ. 
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cells 
ERα+β 
cells 
ERβ 
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Endogenous ERα 
(control adenovirus)  
ERβ (adenovirus 
infected) 
ERβ infected, 
RNAi knockdown of 
ERα  
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Figure 2.2. The effects of different ligands on either ERα or ERβ binding sites were assessed. 
The ligands used in our studies are endogenous ligand E2 (dual activation of ERα and ERβ) and 
the novel, non-steroidal ligands PPT (ERα preferential activation) and ERB-041 (ERβ 
preferential activation). 
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Figure 2.3. Schematic diagram showing locations of tiled probes in the custom-designed tiling 
array. Each probe is 60 bp in length, and probes are tiled ~100 bp from each other. 
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Figure 2.5. A negative control ChIP-chip experiment was done to determine the most suitable 
FDR cutoff value for use in our studies. MCF-7 cells were treated with E2 and 
immunoprecipitated against ERβ. By using a FDR cutoff of 0.2, we detected 17 “potential” 
binding sites (out of the theoretical 0 binding sites in this experiment), which is much lower than 
the current accepted error rates for a ChIP-chip experiment.  
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CHAPTER 3 
LIGAND REGULATION OF CHROMATIN BINDING SITES OF ESTROGEN 
RECEPTORS α AND β: SUBTYPE COMPETITION, MUTUAL RESTRICTION, AND 
LIGAND SELECTIVITY 
 
3.1 ABSTRACT 
Estrogens exert profound effects on the gene expression and biological response programs of 
their target cells, including breast cancer cells. Because these effects on gene expression are 
mediated by two nuclear hormone receptors, estrogen receptor α (ERα) and estrogen receptor β 
(ERβ), that can coexist in the same cells, we explore, in this report, the chromatin binding sites 
for ERα and ERβ, and the interplay of these two receptors when they are present separately or 
together in breast cancer cells. For these studies, we use MCF-7 human breast cancer cells with 
three different complements of these receptors (ERα only, ERβ only, and ERα and ERβ), 
treatment of cells with estradiol (E2), which binds well to both ERs, or with subtype-specific 
ligands that bind to only one of the ERs, and chromatin immunoprecipitation (ChIP)-chip 
analysis with a custom-designed tiling array for ER binding sites across the genome to examine 
the effects of ligand-occupied and unoccupied ERα and ERβ on chromatin binding as 
determinants of gene expression. Our studies demonstrate that there is substantial overlap in the 
chromatin binding sites for E2-liganded ERα and ERβ when they are present alone in cells, but 
that many fewer sites are shared when both ERs are present together. Although each ER subtype 
restricts the binding site occupancy of the other subtype, overall, ERα appears to dominate the 
binding of ERβ, although this is observed only at stimulated genes but not at repressed genes. 
The binding site regions of both ERα and ERβ are markedly enriched in estrogen response 
element (ERE) sequence motifs, and when both ERs are present together, ERα appears to 
displace ERβ so that ERβ binds to sites substantially less enriched in EREs. Studies with ER 
subtype-specific ligands reveal that it is the liganded ER subtype that principally determines the 
 33
sites of chromatin binding. These findings highlight the dynamic interplay between the two ER 
subtypes in their selection of chromatin binding sites, how this is modulated by their state of 
ligand occupancy, and their impact on gene expression.  
 
3.2 INTRODUCTION 
Estrogens play key roles in many aspects of reproductive physiology, development, and 
metabolism, and they are also involved in several disease states, including breast and 
endometrial cancers [1, 2]. The effects of estrogens are mediated through two estrogen receptors, 
estrogen receptor alpha (ERα) and beta (ERβ), that function as ligand-modulated transcription 
factors, up- and down-regulating gene expression in a target tissue-selective manner [3, 4]. The 
presence of ERα in breast cancer cells and in various tissues is associated with enhanced 
proliferation in response to estrogens, whereas several studies have implicated ERβ as exerting 
antiproliferative effects [5-9]. 
ERα and ERβ are highly homologous in their DNA-binding domains (97% identity), but they 
are quite different in their ligand-binding domains (56% identity) and transcriptional activation 
function-1 (18% identity) domains. The differences in their ligand-binding domains allow the 
two ER subtypes to bind certain ligands with high selectivity, for one or the other ER subtype 
[10-13]. Although most human breast cancers co-express both ERs [14-16], much less is known 
about the role of ERβ in breast cancer and how the presence of both ERs might affect cellular 
responses to estrogen, although the presence of ERβ in breast tumors is generally associated with 
a better prognosis [16-20].  
Recently, the chromatin binding sites for the ERα have been mapped on a genome-wide scale 
using chromatin immunoprecipitation (ChIP) combined with either DNA microarray (ChIP-chip) 
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or sequencing (ChIP-PET) analysis [21-24]. These studies have provided an unprecedented view 
of the diversity and distribution of ER binding sites throughout the genome. Unfortunately, most 
of these studies examined only ERα binding, with the exception of the study done by Liu et al. 
[24], that investigated binding sites in only a portion of the genome (chromosomes 1, 3, 6, 21, 
22, X, and, Y) in cells treated with the ER subtype non-selective ligand, E2. Clearly, additional 
studies are needed to examine the characteristics of ERβ binding sites throughout the whole 
genome and to investigate whether ERα and ERβ collaborate and/or compete for these binding 
sites in the presence of E2 and various ER subtype-specific ligands. 
ERs normally function as dimers at chromatin binding sites where they recruit a variety of 
coregulators, histone-modifying enzymes, and other factors to up or downregulate the 
transcription of hundreds of genes that markedly influence cell phenotype [3-5, 25]. It is now 
well documented that ERα and ERβ can exist in cells as homodimers when present alone, and 
additionally as heterodimers when present together [26, 27]. Therefore, to better understand the 
interplay between ERα and ERβ binding at the genomic level, we have used ChIP-chip analysis 
with a custom-designed tiling array to investigate the binding of ERα and ERβ, when present 
together or separately, at all documented high probability and hypothetical estrogen receptor 
binding sites across the genome in MCF-7 breast cancer cells. Specifically, in this work, we have 
used subtype-selective vs. nonselective ligands to examine the effects of ligand-occupied and 
unoccupied ERα and ERβ on chromatin binding events and as determinants of gene expression 
in breast cancer cells. To this end, we have profiled the genome-wide binding events of the two 
ERs in cells containing various complements of ERα and ERβ, treated with either 17β-estradiol 
(E2) or with the ERα-selective agonist PPT [13] or the ERβ-selective agonist ERB-041 [11]. Our 
ChIP-chip studies extend beyond previous large-scale ER binding experiments [21, 22, 24] and 
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demonstrate that there is substantial overlap in the chromatin binding sites for E2-liganded ERα 
and ERβ when they are present alone in cells, but that many fewer sites are shared when both 
ERs are present together. Although each ER subtype restricts the binding site occupancy of the 
other ER, overall, ERα appears to dominate the binding of ERβ. We find that the binding site 
regions of both ERα and ERβ are markedly enriched in estrogen response element (ERE) 
sequence motifs, but when both ERs are present together, ERα appears to displace ERβ. 
 
3.3 MATERIALS AND METHODS 
Ligands, Cell Culture and Adenovirus Infection 
MCF-7 cells were cultured in MEM (Sigma, St Louis, MO), supplemented with 5% calf 
serum (HyClone, Logan, UT), and 100 µg/ml penicillin/streptomycin (Invitrogen, Carlsbad, 
CA). For estrogen-free experiments, the cells were maintained in phenol red-free MEM plus 5% 
charcoal-dextran-treated calf serum for at least 3 days and were then seeded at a density of 3 x 
105 cells per 10 cm tissue culture dish (Corning, Corning, NY) for 2 days before adenovirus 
infection. Recombinant adenoviruses were constructed and prepared as described [3]. Cells were 
infected with either control adenovirus expressing β-galactosidase (Ad) or adenovirus containing 
ERβ (AdERβ) for 72h before ligand treatment. Conditions used were those described previously 
[3, 9] to generate MCF-7 cells expressing levels of ERβ equal to that of the endogenously 
expressed ERα. Estradiol was from Sigma. The ER subtype-selective ligands, PPT and ERB-
041, were synthesized as described [13, 28]. Studies used 10 nM E2, 50 nM PPT, and 500 nM 
ERB-041, concentrations that reflect their relative binding affinities, and give maximal 
occupancy of receptors by these ligands.  
siRNA Transfection 
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siRNA experiments were preformed as previously described, and resulted in knocknown of 
Era mRNA and protein by greater than 95% [4]. siERα sequences (Dharmacon) were: forward, 
5’-UCAUCGCAUUCCUUGCAAAdTdT-3’, and reverse,  5’-
UUUGCAAGGAAUGCGAUGAdTdT-3’.   
ChIP Assays 
ChIP for ERα and ERβ were carried out as described [29] and used the following antibodies: 
ERα antibody HC-20 (Santa Cruz Biotechnology); ERβ antibodies were a combination with 
equal parts of CWK-F12 (produced by our lab) [30], GTX70182 (GeneTex), GR40 
(Calbiochem), and PA1-311 (Affinity Bioreagents). The ChIP DNA was used for ChIP-chip 
analysis and quantitative real-time PCR. 
ChIP-chip Analyses 
The ChIP DNA was hybridized on a custom-designed tiling array produced by NimbleGen. 
The design of the tiling array is described in details in Chapter 2.2. 
 
3.4 RESULTS 
3.4.1 Use of Custom Tiled Microarray of ER Binding Sites 
The custom-designed tiling arrays used in our studies (design methodology described in 
Chapter 2.2) were designed to provide coverage of all known and predicted ER-binding sites 
across the entire genome in MCF-7 cells. MCF-7 cells having the three complements of ER 
(ERα only, ERα+ERβ, ERβ only) were grown in the absence of hormones for at least three days 
and were then treated with control, 0.1% ethanol vehicle or one of the three ligands for a short 
period of time (45 min). Chromatin fragments bound by ER were immunoprecipitated and 
hybridized onto our tiling arrays. We performed three biological replicates (each biological 
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replicate from an independent experiment consisted of two separate hybridizations, technical 
replicates, onto the tiling arrays) to identify enriched binding sites. The raw intensity signals of 
the ChIP-chip experiments were normalized and averaged across the three replicates. The 
binding sites were then identified using the algorithms described in Chapter 2.3. Briefly, ERs 
binding sites are identified from the ChIP-chip results by the intersection of peaks detection (4 or 
more probes whose intensity signals are above a specific threshold) and default false discovery 
rate (FDR) cutoff. The raw ChIP-chip data were processed, and the peak cutoff threshold and 
FDR values were calculated using NimbleGen recommended software, NimbleScan.  
Table 3.1 shows the number of ERα and ERβ binding sites under the various experimental 
conditions. In cells containing ERα only, we probed by ChIP for ERα binding sites (hereafter 
designated ERα[α cells] binding sites); in cells with ERβ only, we probed for ERβ binding sites 
(ERβ[β-cells] binding sites), and in cells containing both ERα and ERβ, we probed for both ERα 
binding sites (ERα[αβ cells] binding sites) and for ERβ binding sites (ERβ[αβ cells] binding 
sites). A number of mock ChIP-chip experiments were also performed to ensure the fidelity of 
our ChIP-chip analyses and to determine the FDR score cutoff (Chapter 2.3). With E2 treatment, 
in MCF-7 cells expressing ERα only, we identified 4405 ERα-binding sites (ERα[α cells] sites); 
in MCF-7 expressing ERβ only, we identified 1897 ERβ-binding sites (ERβ[β cells] sites), and in 
MCF-7 cells expressing both ERα and ERβ, we identified 3252 ERα-binding sites (ERα[αβ cells] 
sites) and 1744 ERβ-binding sites (ERβ[αβ cells] sites) (See Table 3.1).  
 
3.4.2 Validation of ERα and ERβ ChIP-Chip Results 
To confirm the validity of our ChIP-chip dataset, we examined recruitment of the ERs, in the 
three cell-types, on a set of randomly selected binding sites from our ChIP-chip dataset using 
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ChIP-qPCR with antibodies against ERα or ERβ (Figure 3.1). We tested a total of 42 sites and 
validated ER binding in ~91% (39 of 42) of the selected sites. In this respect, our ChIP-chip 
experiments had false-positive error rates of approximately 10%, which are similar to the error 
rates reported in other genome-wide ChIP-chip studies [21, 22]. 
 
3.4.3 ERα has a Dominant Effect on the Distribution of ER Binding 
To understand how the presence of the ER-subtype partner might influence the pattern of 
chromatin binding sites for ERα [in α cells] and ERβ [in β cells], we compared the pattern of 
binding site occupancy by these ERs after E2 exposure in the three cell types. Specifically, we 
compared how ERα binding sites in ERα cells changed when ERβ was also present (i.e., ERα[α 
cells] sites vs. ERα[αβ cells] sites); and conversely, we examined how ERβ binding sites in ERβ 
cells changed when ERα was also present (ERβ[β-cells] sites vs. ERβ[αβ cells] sites). The results 
are visualized in the Venn diagram in Figure 3.2, showing the shift in binding sites occupancy 
with the addition of the other ER subtype partner.  
Intriguingly, in cells containing both ERα and ERβ treated with E2, the presence of ERβ 
restricts the range of binding sites for ERα when compared to that seen in ERα-only cells (3252 
ERα[αβ cells] sites vs. 4405 ERα[α cells] sites). Despite the decrease in the number of ERα[αβ 
cells] binding sites, the overlap between ERα[αβ cells] and ERα[α cells] binding sites is very 
high, with 92% of ERα[αβ cells] binding sites overlapping the ERα[α cells] binding sites (Figure 
3.2A). By contrast, as shown in Figure 3.2B, ERβ[αβ cells] binding sites overlap with only a 
small number of ERβ[β cells] binding sites (806, ~40%). It appears that, in cells containing both 
ERs the presence of E2-liganded ERβ has much less influence on ERα binding site selection than 
does E2-liganded ERα have on the binding site profile of ERβ; in fact, the presence of ERα 
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prevented ERβ from accessing the majority of the binding sites it accessed in ERβ-only cells. 
These data suggest that ERα is more “dominant” in competing for ER binding sites than ERβ 
when the two ER subtypes are coexpressed in the same cells. Curiously, in the presence of ERα, 
ERβ bound to 938 new sites, in fact, to more new sites than to sites it accessed in ERβ-only cells. 
While addition of ERβ caused ERα to bind to some new sites, these represented less than 10% of 
the ERα[αβ cell] sites.  
 
3.4.4 Mutual Competition Between ERα and ERβ Binding Site Occupancy Restricts the 
Number of Potential Heterodimer Sites 
To further evaluate the influence of each ER subtype partner on chromatin binding, we 
examined the occupancy of ER binding sites by ERα and ERβ when they are present either 
separately or together in cells (Figure 3.3A and 3.3B, respectively) after E2 treatment. When 
present separately in cells, ERα or ERβ can each occupy many of the same sites: About 73% of 
ERβ[β cells] binding sites correspond to ERα[α cells] binding sites, though the converse is less, 
with ~31% of the ERα[α cells] binding sites also being accessible to ERβ in ERβ-cells. This is 
consistent with the current knowledge that ERα and ERβ can recognize the same estrogen 
response element motif, and is also consistent with our current observation that ERα appears to 
be the dominant binding subtype. Notably, 28% of the combined total of ERα[α cells] sites plus 
ERβ[β cells] sites represent sites that are in common to both ERs (i.e., can be occupied by either 
ERα or ERβ when present alone). Because both ERα and ERβ have been shown to interact with 
each other and to bind to DNA as heterodimers [31, 32], the ER binding sites common to both 
ERα and ERβ (Figure 3.3A) may represent potential sites for ERα/ERβ heterodimer binding.  
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We next investigated the association of ERα and ERβ binding sites when both receptors are 
present in the cells [αβ cells]. As shown in Figure 3.3B, the ERα [αβ cells] sites and the ERβ [αβ 
cells] sites are much more distinct than were the ERα[α cells] sites and ERβ[β cells] sites. Thus, 
the number of binding sites that can be shared when both ERα and ERβ are present (579) is 
much less than the number of sites that are common (1386) (i.e., can be occupied by either ERα 
or ERβ when present alone). The shared binding sites represent only 13% of the total sites in the 
αβ cells, whereas the binding sites in common to α cells and β cells represented 28% of the total 
binding sites. 
The large reduction in the number of ERα and ERβ binding sites that are shared when both 
ER subtypes are present together suggests again that there is active competition between the two 
receptors for binding at many chromatin sites: When both receptors are present separately, they 
can bind to many of the same sites, because there is no competition from the other ER subtype. 
When they are present together in cells, however, ERα and ERβ compete with each other for 
binding to these common sites, and thus end up sharing a more limited number of binding sites. 
Thus, the number of likely ERα-ERβ heterodimerization sites, measured when both ER subtypes 
are present (579 shared sites), is much smaller than the number of potential ERα-ERβ 
heterodimerization sites (1386 common sites), measured by the overlap of sites for each ER 
alone. Overall, these results clearly implicate a dynamic binding paradigm for ERα and ERβ in 
the presence of their subtype partner and highlight that the two ERs can function as competitors 
that result in a mutual restriction in their chromatin site occupancy when they are present 
together. 
 
 
 41
3.4.5 Sequence Analysis of ERα vs. ERβ Binding Sites 
We next examined whether the genomic sequences to which both ERα and ERβ bind contain 
a recognizable estrogen response element (ERE) motif by performing a DNA-binding motif 
search. We considered a 13-base-pair site with up to two positions varying from the canonical 
ERE (GGTCAnnnTGACC) as a putative ERE motif (full-ERE). Among the ERα[α cells] 
binding regions (Figure 3.4A), 63% contained full-ERE sequences, 23% had ERE half-sites, and 
14% had no ERE-like sequences. The ERE motif distribution in the ERβ[β cells] binding regions 
(Figure 3.4B) was very similar to that of the ERα[α cells] regions. These results support the idea 
that ERα and ERβ, in the absence of their respective ER subtype partners, tend to bind 
predominantly to full EREs.  
To further address whether ERα and ERβ will bind to ERE-like sequences when they are 
present together in the cells, we performed the ERE motif search on the ER binding sites in cells 
expressing both ERα and ERβ. ERα[αβ cells] binding sites have an ERE motif distribution 
(Figure 3.4C) resembling the distribution of the ERα[α cells] sites and ERβ[β cells] sites (Figure 
3.4A and 3.4B, respectively). Surprisingly, we found that the ERβ[αβ cells] binding regions 
(Figure 3.4D) contained a lower percentage of ERE sequences as compared to ERβ[β cells] 
binding regions (Figure 3.4B). In fact, almost one-third of the ERβ[αβ cells] binding site regions 
do not contain any ERE-like (full and half ERE) sequences.  
These observations are a further indication that when both receptors are present in the same 
cells, there is mutual interaction between ERα and ERβ that affects their chromatin binding site 
preferences, with ERα being dominant. Interestingly, ERα dominance over ERβ in chromatin 
binding is most pronounced at ERE-containing sites. This suggests that there is a preference for 
formation of ERα homodimers that drive ERβ in αβ cells to occupy sites less enriched in EREs. 
 42
There is also an alternative possibility, namely that instead of ERβ homodimers being forced to 
occupy new binding sites by the presence of ERα homodimers, ERα/ERβ heterodimers might 
bind preferentially to alternate binding sites, ones that are not occupied by either ER homodimer. 
This possibility could have interesting consequences on the transcriptional output when ERα and 
ERβ are both present in cells. 
 
3.4.6 Correlation Between ER Binding Sites in αβ Cells and E2-Regulated Genes 
Having shown the competitive nature of ERα and ERβ recruitment to the chromatin binding 
sites in cells expressing both receptors, we next investigated the association between ERα and 
ERβ recruitment to cis-regulatory sites and E2-mediated transcriptional responses in ERαβ cells. 
This was accomplished by comparing the promoter regions (10kb upstream and 10kb 
downstream of the transcription start site (TSS)) of 90 genes that are either E2-stimulated or 
repressed in these cells [3] and that have at least one site bound specifically by either receptor 
alone (ERα unique sites or ERβ unique sites) or sites shared by both receptors (ERα/ERβ shared 
sites) (Figure 3.5A).  
Our analysis showed that the promoter regions of E2-repressed genes in αβ cells were three 
times more likely to have binding sites unique to ERβ than to ERα. This suggests that ERβ 
recruited more strongly than ERα to the promoter regions of E2-repressed genes. Intriguingly, for 
E2-stimulated genes, promoter regions were highly (2 fold) associated with binding sites that are 
shared by both ERα and ERβ. These binding sites can be occupied either by an ERα/ERβ 
heterodimer complex or occupied at different times by ERα or ERβ homodimers.  
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A number of studies have previously examined the transcriptional activities of ERβ and ERα 
in breast cancer cells [3, 8], but as far as we know, the results presented here are the first to 
associate ER upstream genome target binding to the transcriptional output of the corresponding 
regulated genes. Although we have shown earlier, on a genome-wide scale, that ERβ may be 
weaker in competing with ERα for binding sites, this study suggests that in the promoter regions 
of some E2-repressed genes, ERβ can successfully compete with ERα and exclude it from 
binding.  
To further characterize ERα and ERβ functional mechanisms and possible co-modulatory 
effects on gene regulation, we monitored ERα and ERβ recruitment to chromatin target sites both 
upstream and downstream of the transcription start site of the well known E2-regulated gene, 
FOS, in the three cell-types after E2 treatment. We first measured the transcript level of FOS by 
quantitative RT-PCR in response to E2 treatment in the three cell types (Figure 3.5B). In both 
ERα-only and αβ cells, the E2-stimulated expression of FOS was very similar; however, we saw 
a reduced (ca. 40%) expression of FOS in cells expressing only ERβ. This suggested that ERβ 
might be a weaker transcriptional activator of this gene relative to ERα.  
We then examined both ERα and ERβ recruitment to three potential ER binding sites 
(identified by our ChIP-chip data) by ChIP-qPCR. The sites are denoted as FOS_enh1, 
FOS_enh2 and FOS_3’end. The first two sites are located ~20kb upstream, whereas the third is 
located ~5kb downstream of the FOS TSS. The binding data is shown in Figure 3.5C. We 
observed that ERα and ERβ could bind to the FOS_enh2 site in all three types of cells and was 
not affected by the presence of its ER subtype partner; however, FOS_enh1 and FOS_3’end sites 
were bound exclusively by ERα. We hypothesize that either one or both of these sites 
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(FOS_enh1 and FOS_3’end) are responsible for the enhanced transcription of FOS seen in ERα-
only and in ER αβ cells.  
This hypothesis was tested by comparing PolII ChIP-chip data published by Carroll et al. 
[21] with the ER binding sites around FOS. PolII binding was detected at three separate sites in 
the vicinity of the FOS TSS. Interestingly, we found that one of the PolII sites was located at 
FOS_enh1 (ERα-exclusive binding site). The PolII data suggests that the enhanced FOS 
transcript level in ERα-only and ERαβ cells might be due to the recruitment of additional PolII 
by ERα to the FOS_enh1 site, which might then bring the recuited PolII to the TSS of FOS, 
perhaps by a looping mechanism [33]. This would be consistent with the reduced FOS 
expression in ERβ-only cells, because ERβ does not access the FOS_enh1 site, so no additional 
PolII would be brought to the TSS of FOS by ERβ. 
 
3.4.7 Binding Site Distribution with the ERα-Selective Ligand (PPT) vs. E2 
To assess the effect of the ERα-selective ligand, PPT, on ERα chromatin binding, we 
examined binding site occupancy after PPT exposure in ERα-only or ERαβ cells (Table 3.1). We 
found that the ERα binding sites, after PPT treatment, were very similar to those observed after 
E2 treatment (Figure 3.6A and 3.6B). In ERα-only cells, 92% of ERα binding sites after PPT 
treatment were also found in the E2 treatment group, and in ERαβ cells, 83% of ERα binding 
sites after PPT treatment were the same as the ERα binding sites from the E2 treatment group. 
The data suggests that the ERα-PPT complex formed is quite similar to the ERα- E2 complex in 
terms of enabling ERα to access the chromatin binding sites to which ERα binds in both ERα-
cells and ERαβ-cells.  
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In contrast to E2, PPT has extremely low affinity for ERβ, less than 0.2% that of E2 [13]; 
therefore, it is very unlikely to bind to or activate ERβ in cells containing both ERs. Therefore, 
we hypothesized that in ERαβ-cells, the unliganded ERβ would be unable to compete effectively 
against the ERα-PPT complex for ER binding sites. Consistent with this hypothesis was the 
ChIP-chip data showing that the number of ERα[αβ cells] binding sites increases from 3252 to 
3466 binding sites when these cells are treated with PPT as compared to E2. This slight increase 
in ERα[αβ cells] binding sites after PPT treatment is consistent with the concept that activated 
ERα and ERβ act as competitors when they are present in the same cells, but that unoccupied 
ERβ is less effective as a competitor of ERα for chromatin binding. 
 
3.4.8 Binding Site Distribution with the ERβ-Selective Ligand (ERB-041) vs. E2 
In addition to our ChIP-chip analysis of ERα chromatin binding after PPT treatment, we also 
characterized the chromatin binding of ERβ after treatment with ERB-041, an ERβ-selective 
ligand [11], in MCF-7 cells containing either ERβ-only or both ERα and ERβ. We found that 
when treated with ERB-041, ERβ bound to 1042 sites in ERβ-only cells and 1109 sites in ERαβ 
cells (Table 3.1). After ERB-041 treatment, ERβ bound to many ER sites different from those 
following E2 treatment. In ERβ-cells after ERB-041 treatment, only 51% of the ERβ binding 
sites overlapped the ERβ binding sites in the E2 treatment group (Figure 3.6C). Similarly, in 
ERαβ-cells, only 47% of the binding sites bound by ERβ after ERB-041 treatment overlapped 
the sites bound by ERβ after E2 treatment (Figure 3.6D).  
These results provide an indication of the complexity in relating the conformation and 
activation of the different ER-ligand complexes to their recruitment at chromatin target sites. The 
ERα-PPT complex behaves in a manner much like that of the ERα- E2 complex, binding to many 
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of the same sites, and the addition of ERβ (occupied in the presence of E2, but unoccupied in the 
presence of PPT) has relatively little affect on ERα binding (Figure 3.6A and 3.6B). In contrast, 
the ERβ-ERB-041 binding sites are often not the same as those of the ERβ-E2 complex. While 
this suggests that the conformations induced in ERβ by the binding of ERB-041 vs. E2 might be 
different, this is not apparent from a comparison of their X-ray crystal (PDB entry 2j7x for ERβ 
with E2 (unpublished) and 1x7b for ERβ with ERB-041 [28]).  
 
3.4.9 Overlap of ERα and ERβ Binding Sites with Subtype-Selective Ligands 
After characterizing the patterns of chromatin binding by ERα and ERβ when liganded by 
their corresponding subtype-selective ligands vs. E2, we further examined the relationship 
between ERα-PPT and ERβ-ERB-041 chromatin binding sites. First, we compared ERα[α cells] 
binding sites with ERβ[β cells] binding sites (Figure 3.7A). Previously, we had defined the 
overlap of binding sites in this case as sites “in common” to ERα or ERβ, meaning that these 
sites could be occupied by either ER subtype, provided that the other subtype was not present. 
Curiously, there were fewer ERα-PPT[α-cells] and ERβ-ERB-041[β-cells] sites in common 
(509) than were in common when ERα and ERβ were bound with E2 (1386, Figure 3.3A). This 
suggests that the conformation induced by the binding of a subtype-selective ligand to its 
respective ER subtype is not precisely the same as that induced by the binding of E2, and as a 
result, ERα and ERβ bound by their respective subtype-specific ligands have more distinct 
binding preferences than do the E2-bound ER subtypes, meaning fewer sites in common.  
We next investigated the relationship between ERα[αβ cells] binding sites with ERβ[αβ cells] 
binding sites (Figure 3.7B). These were sites previously defined as “shared” by ERα and ERβ, 
meaning that either one or both of the receptors could bind to these sites when both were present 
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in cells (Figure 3.3B). Interestingly, in ERαβ cells, when one or the other of the ER subtype was 
occupied by its respective subtype-specific ligand, there were, in fact, a larger number of sites 
shared by ERα and ERβ (730) than when both ERs were co-occupied by E2 (579) (compare 
Figure 3.3B and Figure 3.7B). Because PPT and ERB-041 are ER subtype-selective ligands, 
when ERαβ cells are treated with one or the other of these ligands, one of the ER subtypes will 
be liganded but the other will be unliganded. The greater number of shared sites when the 
subtype-selective ligands are used, indicates that unoccupied ERs are less able to compete with 
occupied ERs for the same binding sites. This is consistent with our previous data showing that 
both ERs compete with one another quite well when they are present together in the cells 
following E2 treatment, in which case, both ERs will be occupied by E2 because it binds well to 
both ERα and ERβ.  
 
3.5 DISCUSSION 
Previous studies done by our group and others [3, 4, 25, 34] have shown that ERβ has a 
significant impact in modulating the expression of genes regulated by ERα in breast cancer cells. 
However, understanding this orchestrated transcriptional program by both ERα and ERβ will not 
be complete without the examination and identification of the chromatin targets of ERα and ERβ 
when they are either separately or present together in breast cancer cells under various treatment 
conditions. Therefore, in this study, we seek to identify, in a genome-wide level, the chromatin 
localizations of ERα and ERβ in MCF-7 breast cancer cells and examine how ER selection of 
chromatin binding sites is affected by their state of ligand occupancy.  
When both receptors are coexpressed in the cells, we observed that the number of binding 
sites that can be shared by both ERα and ERβ is very much reduced (579 sites, Figure 3.3B) 
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compared to the number of sites that are common (1386 sites, Figure 3.3A). This result suggests 
that, on a genome scale, there is active competition between the two receptors for chromatin 
binding sites when they are present together in cells and they can no longer bind unobstructed to 
their native binding sites as in the case when they are present alone in the cells, therefore ending 
up sharing a much limited set of binding sites. In order to examine the how the presence of their 
subtype partner has on ER binding activities, we assessed the binding profile of ERα and ERβ in 
the copresence or absence of its isoform partner. We found that 92% of ERα[αβ cells] binding 
sites overlap ERα[α cells] binding sites and 40% of ERβ[αβ cells] binding sites overlap ERβ[β 
cells] binding sites. Like in all competitive interactions, there will be a dominant player and our 
results indicate that ERα is the more dominant isoform as it appears that the presence of ERβ has 
a small influence on ERα binding sites selections since ERα[αβ cells] binds to most of its native 
sites (ERα[α cells]) despite the presence of liganded ERβ. But the presence of liganded ERα has 
a greater influence on perturbing ERβ chromatin binding site profile with ERβ[αβ cells] binding 
to new alternative binding sites differ from their native binding sites (ERβ[β cells]). Overall, 
from a systemic point of view, our results exemplify the competitive nature of ERα and ERβ in 
chromatin binding with ERα being more “dominant” in competing for ER binding sites and also 
the binding dynamism of the two ER subtypes with ERβ binding to new alternative sites less 
enriched in EREs when it native binding sites were bound by ERα. 
A number of studies have previously examined the transcriptomic activities of ERα and ERβ 
with the bulk of evidence implying that ERβ has growth-suppressive activities [5-7]. Our ChIP-
chip analyses in ERαβ cells have revealed new mechanistic insight into ERβ modulated gene 
expression. Our analysis showed that the promoter regions of certain E2 repressed genes were 
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three times more likely to have binding sites bound exclusively by ERβ. Although ERα may be 
the dominant ER isoform, but intriguingly, within the promoter regions of these E2-repressed 
genes, ERβ is able to compete and exclude ERα from binding. This transcriptional signaling 
activity may be, at least in part, responsible for ERβ growth-suppressive activities. The results of 
our sequence analysis (Figure 3.4) revealed that both ERα[α cells] and ERβ[β cells] are binding 
mostly to chromatin targets containing ERE motifs. This observation fits well with the current 
consensus that ERα and ERβ both appear to recognize the same estrogen response element 
motif. The interesting observation is that although the ERE motif distribution of ERα[αβ cells] 
binding regions is very similar to distributions found in both ERα[α cells] and ERβ[β cells] 
binding regions but ERβ[αβ cells] is binding to sites which contained a lower percentage of ERE 
sequences. This is likely the reflection of the competitive nature of the two ER isoforms when 
they are coexpressed in the same cells; ERβ[αβ cells] being denied of its native sites by the 
dominant liganded ERα will have to occupy alternative binding sites less enriched with EREs. 
We also examined the impact of subtype-selective ligands on the chromatin binding profiles 
of ERα and ERβ. Our Chip-chip analysis showed that most of the sites bound by ERα[α cells] 
and ERα[αβ cells] after PPT treatment were also found in the E2 treatment group (Figure 3.6A 
and 3.6B), suggesting that the conformation change of the ERα-PPT complex should be quite 
similar to the ERα-E2 complex thus enabling similar access to the chromatin. However, we 
noted that the sites bound by ERβ[β cells] and ERβ[αβ cells] after ERB-041 treatment are quite 
distinct from the binding sites in the E2 treatment group (Figure 3.6C and 3.6D). Only 
approximately half of the ERβ binding sites are shared between the two treatment groups 
indicating that the conformations induced on the ERβ complexes by E2 and ERB-041 might be 
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different. Intriguing, a comparison of their X-ray crystal shows that the ERβ conformations by 
the two ligands are very similar suggesting that it might be due to the differences in recruiting 
certain cofactors by the different liganded ERβ complexes, which may determine chromatin 
accessibility. Altogether, our data reveal the additional complexity in relating the conformation 
of the different ER-ligand complexes to their recruitment to chromatin in vivo. Our analysis 
showed that the number of shared sites (either one or both of the receptors can bind in ERαβ 
cells) increased when the ER subtype was occupied by its respective subtype-specific ligand 
compared to both ERs co-occupied by E2 (Figure 3.7B v.s. Figure 3.3B). The increase in number 
of shared sites when the subtype-selective ligands are used indicates that it is the liganded ER 
subtype that principally determines the location of the chromatin binding sites. 
There is abundant evidence that in addition to ERα, ERβ plays a critical role in human breast 
cancer as ER-positive human breast cancers usually contain both ERα and ERβ. Our ChIP-chip 
analysis of both ERs provides us with genome scale snapshots of ERs’ cis-regulatory elements 
which can help us elucidate the activities of both ERs and how each ER subtype will impact the 
binding profile of the other subtype in breast cancer. Our work suggests that when both ER 
subtypes are present in the cells, they each restrict the other ER from accessing their preferred 
binding sites but overall, ERα appears to be the dominating ER subtype. Our studies also 
indicate that there is a tendency for both ERα and ERβ to bind to sites enriched with EREs. Our 
data further define on a genome scale the chromatin binding sites of ERα and ERβ under 
subtype-selective ligands treatment. The results point to an important role of the liganded ER; 
that it is principally responsible for determining the selection of chromatin binding sites. Taken 
together, our ChIP-chip studies provide insights to the dynamic interplay between ERα and ERβ 
in selecting and competing for chromatin binding sites in breast cancer cells. 
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3.6 TABLE AND FIGURES 
 
Table 3.1. Summary of ER binding sites in the three MCF-7 cells expressing ERα only, both 
ERα and ERβ, or ERβ only. 
 
 
 
 
 
 
 
 
 
 
 
*Values are the mean from three independent experiments, with each experiment done in 
duplicate. 
 Cell Type Ligand Antibodies Binding sites* 
1         MCF7 [α cells] E2 anti-ERα 4405 
2         MCF7 [α cells] PPT anti-ERα 3269 
3         MCF7 [αβ cells] E2 anti-ERα 3252 
4         MCF7 [αβ cells] E2 anti-ERβ 1744 
5         MCF7 [αβ cells] PPT anti-ERα 3466 
6         MCF7 [αβ cells] ERB-041 anti-ERβ 1109 
7         MCF7 [β cells] E2 anti-ERβ 1897 
8         MCF7 [β cells] ERB-041 anti-ERβ 1042 
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Figure 3.1. Validation of ChIP-chip binding sites. ERα and ERβ chromatin binding (by 
conventional ChIP assays) were measured by quantitative PCR after 45min of E2 treatment of 
MCF-7 cells differentially expressing ERα and/or ERβ. Data are expressed as recruitment index 
(ER ChIP/Input) and is the average of two replicates. Binding sites are considered validated if 
the recruitment index is >2. ChIP-qPCR results are shown for (from left to right) ERα 
recruitment in ERα-only cells, ERα recruitment in cells containing both ERs, ERβ recruitment in 
cells containing both ERs, and ERβ recruitment in ERβ-only cells. 
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Figure 3.2. Effect of ER subtype partner on ER binding site distribution with E2 treatment. (A) 
The introduction of ERβ into the cells has a relatively minor effect on the distribution of ERα 
binding sites. (B) ERα has a more pronounced effect on the distribution of ERβ binding sites. 
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Figure 3.3. Venn diagrams comparing the occupancy of ER binding sites by ERα and ERβ when 
they are present either separately or together in cells treated with E2 (A) ERα or ERβ can each 
occupy many of the same sites when the other ER subtype is not present in the cells. (B) When 
both receptors are present in the cells, ERα and ERβ share a more limited number of sites.  
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Figure 3.4. Presence of ERE sequences in ERα or ERβ binding sites with E2 treatment. Binding 
sites were probed for the presence of full ERE (allowing for up to two base deviations from the 
canonical ERE), half ERE, and no ERE motifs. (A) ERα binding sites in ERα-only cells. (B) 
ERβ binding sites in ERβ-only cells. (C) ERα binding sites in cells containing both ERα and 
ERβ receptors. (D) ERβ binding sites in cells containing both ERα and ERβ receptors. 
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Figure 3.5. Correlation between ER binding and transcriptional output in response to E2. (A) 
Correlation between E2-regulated genes and binding of ERα-unique (only ERα binds), ERβ-
unique (only ERβ binds), or ERα/ERβ (the sites are shared by both ERs) within + 10kb of the 
TSS of the genes. (B) FOS mRNA levels were assessed by quantitative PCR after 4hr treatment 
of MCF-7 cells differentially expressing ERα and/or ERβ. Data represent average fold change + 
SD for three independent replicates. (C) ERα and ERβ chromatin binding (by conventional ChIP 
assays) were measured by quantitative PCR after 45min E2 treatment of MCF-7 cells expressing 
ERα and/or ERβ. ERα and ERβ occupancy of three different ER binding sites that are closest to 
the FOS gene are presented graphically. Enh., denotes enhancer. 
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Figure 3.5. (cont.) 
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Figure 3.6. Venn diagrams comparing ER binding site occupancy after cell treatment with the 
ERα-selective ligand (PPT) or ERβ-selective ligand (ERB-041) vs. E2. (A) ERα binding sites in 
ERα-only cells (E2 vs .PPT treatment). (B) ERα binding sites in cells containing both ERα and 
ERβ (E2 vs. PPT treatment). (C) ERβ binding sites in ERβ-only cells (E2 vs. ERB-041 
treatment). (D) ERβ binding sites in cells containing both ERα and ERβ (E2 vs. ERB-041 
treatment). 
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Figure 3.7. Venn diagrams showing the overlap of ERα binding sites (PPT treatment) and ERβ 
binding sites (ERB-041 treatment). (A) ERβ binding sites in ERβ-only cells (ERB-041 
treatment) and ERα binding sites in ERα-only cells (PPT treatment). (B) ERβ and ERα binding 
sites in cells containing both ERα and ERβ (ERB-041 vs. PPT treatment). 
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CHAPTER 4 
A NETWORK OF ESTROGEN RECEPTORS α AND β, AND COREGULATORS SRC3 
AND RIP140, IN BREAST CANCER TRANSCRIPTIONAL REGULATION 
 
4.1 ABSTRACT 
The nuclear hormone receptors, ERα and ERβ, are known to regulate the transcriptional 
response programs of their target cells, including breast cancer cells. However, their comparative 
abilities to localize at chromatin binding sites across the genome, and the association of these 
receptor binding sites with binding sites for the major coregulators SRC3 and RIP140, and with 
other transcription factors and chromatin remodeling factors is incompletely understood. 
Therefore, in these studies, we have used ChIP-seq in breast cancer cells containing three 
different complements of ERs (ERα alone, ERβ alone, or ERα + ERβ) treated with estradiol to 
define the cartography of chromatin binding sites for ERα, ERβ, and the coregulators SRC3 and 
RIP140. We have found that ERα and ERβ bind to a similar, large number of sites (ca. 38,000) in 
cells containing only one ER subtype, with ERα sites being preferentially enriched in GATA and 
FOXA1 motifs, and ERβ sites preferentially enriched in E2F motifs. Although the two ERs 
occupy fewer sites in ERα + ERβ cells (ca. 20,000), the enrichment of their preferentially co-
associated transcription factor motifs is further accentuated in the ERα and ERβ binding sites in 
these cells. Further, ERα was found, in general, to occupy chromatin sites more depleted of 
intrinsic nucleosomes compared to ERβ. Gene chip microarray transcriptional profiling and gene 
ontology analysis delineated a core set of genes that correlate with ERα proliferative and ERβ 
anti-proliferative effects in breast cancer cells. ERβ activation by estradiol was associated with 
the inhibition of genes associated with cell proliferation and the up-regulation of pro-apoptotic 
genes and genes responding to DNA damage, whereas ERα activation was associated with the 
downregulation of pro-apoptotic genes and genes repressing transcription. Analysis of chromatin 
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binding of SRC3 and RIP140 by ChIP-seq revealed that these coregulators are recruited 
preferentially to ER binding sites of estrogen-induced genes, whereas they are seldom recruited 
to ER binding sites of hormone-repressed genes, indicating that the SRC3-RIP140 complex is 
likely to be playing a central role in the induction of ER targeted genes. Our findings suggest an 
integrated model in which the actions of cofactors such as FOXA1, GATA3, and E2F enforce 
the selectivity and range of ERα and ERβ binding and gene regulatory actions, with the 
coregulators SRC3 and RIP140 preferentially supporting the stimulatory actions of both 
receptors on gene expression. 
 
4.2 INTRODUCTION 
Estrogens play pivotal roles in reproductive physiology, development and metabolism. 
Estrogens are also involved in several disease states, including breast and endometrical cancers 
as well as osteoporosis [1, 2]. Estrogen receptor alpha (ERα) and beta (ERβ) belong to the 
superfamily of nuclear transcription factors that mediate the actions of estrogens. It has been 
well-documented by various studies [3, 4] that the presence of ERα in breast cancer cells results 
in enhanced proliferation in response to estrogens. The role of ERβ and the manner in which it 
can impact estrogen mitogenicity in breast cancer, however, are less clear, although several 
reports have implicated ERβ as a negative regulator of ERα and shown that ERβ has 
antiproliferative effects in breast cancer cells [5-10]. As yet, however, no studies have 
convincingly identified genes that can explain ERα proliferative and ERβ anti-proliferative 
actions in breast cancer cells.   
When ERα and ERβ bind estrogen, they undergo a conformation change that releases heat 
shock proteins and enhances ER dimerization and subsequent binding to the regulatory regions 
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of their target genes. Once bound on the chromatin, the activated ERs will recruit coregulators to 
form a multiprotein complex that activates the general transcriptional machinery which then 
regulates the expression of target genes [11, 12]. We have earlier demonstrated that the 
coregulators steroid receptor coactivator 3 (SRC3) and receptor interacting protein of 140kDa 
(RIP140) are recruited by both ERα and ERβ [4].  
RIP140 is an atypical coregulator as it can act either as a coactivator or corepressor. Since its 
identification as a ERα coregulator [13], RIP140 has been found to interact with many other 
nuclear receptors, such as AR, GR, VDR, etc. [14-16]. RIP140 transactivation on ERα was 
observed in yeast [17, 18] and transient transfection of RIP140 expression plasmid leads to 
increase in ERα activity [13, 19]. Paradoxically, published data also indicate the repressive 
effects that RIP140 has on gene transcription. In one study, transrepression activity was observed 
on a reporter gene by full-length RIP140 fused to a GAL4-DBD [20], while global gene 
expression analysis in another study revealed that a significant number of genes were increased 
in RIP140-null cells as compared to RIP140-expressing wild-type cells [21]. SRC3, also known 
as amplified in breast cancer-1 (AIB1) [22], is a coactivator that promotes the transcriptional 
activity of ERα [22, 23]. Depletion of SRC3 led to a reduction of estrogen-stimulated 
proliferation in MCF-7 cells [24, 25].  
Given the intimate relationships between ERs, coregulators, and gene expression, we 
hypothesize that we can better understand and dissect the differences in ERα- and ERβ-mediated 
transcriptional programs in breast cancer by an integrative genomic approach utilizing ERα and 
ERβ chromatin localization and the co-recruitment of SRC3 and RIP140 to ER binding sites. 
First, we employed chromatin immunoprecipitation (ChIP) combined with sequencing (ChIP-
seq) to map the genomic landscape of ERα, ERβ, SRC3, and RIP140 in breast cancer cells 
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containing various complements of ERα and ERβ, in the presence of 17β-estradiol (E2). Next, 
gene expression microarray analyses were carried out to investigate the gene regulatory effects 
of ERα and ERβ in breast cancer cells. Finally, by correlating the global cartographies of ERα, 
ERβ, SRC3, and RIP140 with the results of the gene expression microarray analyses, we present 
evidence of ERs direct target genes that may contribute to ERα proliferative and ERβ anti-
proliferative nature of these receptors in breast cancer cells. Our integrative ChIP-seq and 
expression profiling study extends beyond previous large-scale ER binding and gene expression 
studies [3, 4, 7-10, 26-32], because in this study we have comprehensively studied the 
recruitment of ERs (both ERα and ERβ, alone or together), together with their coregulators, to 
chromatin and the subsequent transcription impact effected by ERs on their target genes in breast 
cancer cells containing various complements of ERα and ERβ. We demonstrate that the 
selectivity and range of ERα and ERβ binding to the chromatin appear to depend on different 
cofactors. Our findings highlight the critical role of SRC3-RIP140 complex in breast cancer cell 
proliferation: The ERα-SRC3-RIP140 transcriptional program defines breast cancer 
proliferation, whereas the ERβ-SRC3-RIP140 program acts to positively regulate apoptosis in 
breast cancer cells. 
 
4.3 MATERIALS AND METHODS 
Ligands, Cell Culture and Adenovirus Infection 
MCF-7 cells were cultured in MEM (Sigma, St Louis, MO), supplemented with 5% calf 
serum (HyClone, Logan, UT), and 100 µg/ml penicillin/streptomycin (Invitrogen, Carlsbad, 
CA). For estrogen-free experiments, the cells were maintained in phenol red-free MEM plus 5% 
charcoal-dextran-treated calf serum for at least 3 days and were then seeded at a density of 3 x 
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105 cells per 10 cm tissue culture dish (Corning, Corning, NY) for 2 days before adenovirus 
infection. Recombinant adenoviruses were constructed and prepared as described [10]. 
Conditions used were those described previously [10, 28, 33] to generate MCF-7 cells expressing 
levels of ERβ equal to that of the endogenously expressed ERα. Estradiol was from Sigma. The 
ER subtype-selective ligands, PPT and ERB-041, were synthesized as described [34, 35]. Studies 
used 10 nM E2, 50 nM PPT, and 500 nM ERB-041, minimal concentrations found to be 
maximally effective in binding to ERα and ERβ (E2), ERα (PPT), and ERβ (ERB-041), 
respectively, based on their relative binding affinities for receptor and their ability to regulate 
gene expression, based on our prior work [28]. 
siRNA Transfection 
siRNA experiments were preformed as previously described, and resulted in knocknown of 
ERα mRNA and protein by greater than 95% [4]. siERα sequences (Dharmacon) were: forward, 
5’-UCAUCGCAUUCCUUGCAAAdTdT-3’, and reverse,  5’-
UUUGCAAGGAAUGCGAUGAdTdT-3’.   
ChIP Assays 
ChIP for ERα, ERβ, SRC3, and RIP140 were carried out as described [36] and used the 
following antibodies: ERα antibody HC-20 (Santa Cruz Biotechnology); ERβ antibodies were a 
combination with equal parts of CWK-F12 (produced by our lab) [37], GTX70182 (GeneTex), 
GR40 (Calbiochem), and PA1-311 (Affinity Bioreagents); SRC3 antibody H-270 (Santa Cruz 
Biotechnology); RIP140 antibody (Santa Cruz Biotechnology). The ChIP DNA was used for 
ChIP-seq analysis and quantitative real-time PCR.  
ChIP-seq Analyses 
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The ChIP DNA was prepared into libraries and sequenced using the Genomic Analyzer 
following Illumina protocols. Sequences generated were mapped uniquely onto the human 
genome (hg18) by ELAND. MACS [38] was used to identify enriched peak regions with a p-
value cutoff of 6.0e-7 and FDR of 0.01. 
GeneChip mRNA transcriptional profiling microarrays 
Total RNA was used to generate cRNA, which was labeled with biotin according to 
techniques recommended by Affymetrix. The biotin-labeled cRNA was then hybridized to 
Affymetrix U133 plus 2.0 GeneChips, which contain oligonucleotide probe sets for over 47000 
transcripts. After washing, the chips were scanned and analyzed using Affymetrix processing 
software. CEL files were processed using GeneSpring GX 11.0 software (Agilent) to obtain fold-
change and p-value (with Benjamini and Hochberg multiple test correction) for each gene for 
each treatment relative to the vehicle control. We considered genes with fold-change > 1.5 and p-
value < 0.05 as statistically significant, differentially expressed. 
Motif and GO category Analysis 
Overrepresented GO biological processes were determined by the web-based DAVID 
Bioinformatics Resources database [39, 40]. Motifs enrichment analysis was done using 
MotifEnrich program which uses TRANSFAC PWMs for motifs discovery (Ken Sung 
unpublished data). 
 
4.4 RESULTS 
4.4.1 Genes Are More Likely to be Up-Regulated in the Presence of ERβ as Compared to ERα 
We sought to determine ERα and ERβ mediated transcriptional responses in breast cancer 
cell by performing gene expression profiling. Cells were treated for 4 hours with estradiol 
 68
followed by hybridization of total RNA onto Affymetrix U133 plus 2.0 arrays (Figure 4.1A). For 
reference, since E2 activates both ERs, we also performed gene expression analysis using PPT, 
an ERα-selective ligand [35], and ERB-041, an ERβ-selective ligand [41] (Figure 4.1B). 
Triplicate experiments were performed, and analysis revealed that globally, genes were more 
likely to be up-regulated in the presence of ERβ compared to ERα (see Figure 4.1). For example, 
upon E2 treatment, 45% and 66% of the genes were up-regulated in cells containing ERα only 
([α cells]), or ERβ only ([β cells]) respectively. This pattern of response is further reinforced 
when we compared the gene expression profiles in cells containing both ERα and ERβ ([αβ 
cells]) under PPT and E2 treatment. Under conditions where ERβ is not activated (PPT treatment 
in [αβ cells]), we find the percentage of up- and down-regulated genes by PPT to be very similar 
to E2 treatment in [α cells]. However, upon E2 treatment in [αβ cells] (which activated both ERα 
and ERβ), we observe a reversal with more genes being being up-regulated, indicating the 
preference for ERβ to up-regulate genes. In [β cells], we observed that globally ~65% of the 
genes were up-regulated by both E2 and ERB-041 treatments. 
 
4.4.2 Global Analysis of Cellular Processes Regulated Uniquely by ERα and ERβ 
Because ERβ has been implicated in the inhibition of cell proliferation while ERα is linked to 
proliferative activities [3, 7, 8], we therefore asked whether genes differentially regulated by 
ERα and ERβ have different underlying biological functions that can provide clues to the 
differences between the functional activities of the two ERs. Specifically, we focused our 
examination by looking at genes that are uniquely regulated by the respective ERs (see Figure 
4.2A for the gene clusters that were examined) upon E2 treatment. We used DAVID [39, 40] to 
test for overrepresented gene ontology (GO) biological processes in the three gene clusters.  The 
ERα-only gene cluster showed GO terms of “apoptosis” and “transcription repressor activity” as 
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overrepresented. Interestingly, most of the genes in these two GO categories are E2 repressed 
(see Figure 4.2B). By looking further into the GO descriptions of the group of apoptotic genes, 
we found 34% of these genes are pro-apoptotic, and 7% are anti-apoptotic (55% of the genes do 
not have further GO descriptions indicating whether they are pro- or anti-apoptotic). Our 
findings extend the results of previous studies [3, 10] by implicating that ERα proliferative 
activities may be through the down-regulation of apoptotic (mostly pro-apoptotic) and 
transcription repressor genes. 
We found the GO terms of “programmed cell death” and “response to DNA damage” to be 
overrepresented in the ERβ-only cluster. Similarly, by looking further into the GO descriptions 
of the group of “response to DNA damage” genes, we found 33% are pro-cell death, and 12% 
are pro-proliferation (56% of the genes do not have further GO descriptions to indicate whether 
or not they are pro-proliferative or cell death inducing). The majority of the “programmed cell 
death” genes are pro-apoptotic (55% vs. 10% that are anti-apoptotic). In contrast to the ERα-only 
cluster, most of the ERβ-only cluster genes (“programmed cell death” and “response to DNA 
damage”) are up-regulated by E2 (see Figure 4.2C). The GO analysis suggest that ERβ activation 
may play a role in the inhibition of cell proliferation through the up-regulation of pro-apoptotic 
genes and genes responding to DNA damage.  
 
4.4.3 ERβ has the Ability to Modulate and to Replace ERα Functions 
Motivated by the results in Section 4.4.2 and studies from other labs [3, 5-7, 9, 42] that show 
ERα proliferative and ERβ anti-proliferative actions in breast cancer cells, we selected several 
well-known cell-cycle and proliferation genes and compared their gene expression in cells 
containing various complements of ERα and ERβ. Cell cycle genes have been implicated directly 
in tumorigenesis, and their expression has been reported to coincide with cellular transformation 
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and oncogenic potential [43, 44]. The cell cycle and tumor proliferation genes (shown in Table 
4.1) were selected from [45, 46].  
We took the list of genes and extracted the patterns of gene expression from our E2-treated 
gene expression profile study (described in section 4.4.1). Interestingly, we observed that, similar 
to ERα, ERβ was able to induce a set of cell cycle and proliferation genes. However, this is not a 
complete replacement, as ERβ induction of these genes is mostly weaker than ERα induction 
(compare Figure 4.3A, ERα cells vs. ERβ cells). Taken together, our in vitro data suggests that 
ERβ is taking over some of the roles of ERα (upon the lost of ERα expression) in order to 
maintain normal MCF-7 cell functions.  Also, ERβ is not inducing these genes as robustly as 
ERα, further indicting that ERβ is acting as, possibly, only a partial replacement.  By contrast, 
while some genes are up-regulated by both ERα and ERβ (Figure 4.3B), most of the cell cycle 
and proliferation genes are down-modulated by ERβ (compare Figure 4.3A, ERα cells vs. ERαβ 
cells) in the presence of ERα. Taken together, these results further reinforce our previous 
findings [4, 10] that ERβ has the ability to modulate ERα-mediated transcriptional activity and 
ERβ may attenuate MCF-7 growth by repressing ERα-regulated cell cycle and proliferative 
genes when both ERs are present together in the cells. 
ERβ mainly plays an anti-proliferative role in breast cancer but apparently primarily in the 
presence of ERα where it modulates ERα signaling and represses ERα proliferative effects. 
However, upon the loss of ERα, ERβ might have the ability to replace some of ERα signaling in 
order to maintain normal cell functions. We therefore speculate that in MCF-7 cells, in addition 
to the ability of ERβ to modulate ERα signaling when both of them are present in the cells, ERβ 
can take over some of ERα signaling upon loss of ERα (i. e., in ERβ-only cells). This would 
indicate an extraordinary role of ERβ as a bifunctional switch that may be activating in one 
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setting and repressive in another. More detailed studies are required to elucidate the ability of 
ERβ to replace ERα functions upon the loss of ERα expression. 
 
4.4.4 Genome-Wide Analysis of ERα and ERβ Chromatin Binding by ChIP-Seq 
In a preliminary study, we investigated ER-binding site selection by ERα and ERβ in human 
breast cancer cells [28] by ChIP-chip (Chapter 3). However, this initial assessment was limited 
by the fact that the analysis was not genome-wide, as the NimbleGen array was custom-designed 
based on known ERα binding sites and other computationally predicted sites. Therefore, the 
NimbleGen array used in our ChIP-chip study was not able to detect binding sites unique to ERβ. 
To obtain a more global and unbiased picture of ERα and ERβ binding sites, we generated ChIP-
seq libraries to study the genome-wide localization of ERα and ERβ, when present separately or 
together, in response to E2 treatment (Methods, Table 4.2). Due to the unbiased and genome-
wide manner of sequencing, the ChIP-seq ER datasets described in this chapter should represent 
all ERα and ERβ binding sites in MCF-7 cells. Therefore, we wished to validate the two major 
findings from our ChIP-chip study, namely (i) the constriction of ERα binding sites by ERβ and 
(ii) the shunting of ERβ to less “favorable” ERE binding sites, using the more comprehensive 
ChIP-seq datasets.   
First, we observed from the ChIP-chip study that in cells containing both ERα and ERβ, the 
presence of ERβ restricts the range of binding sites for ERα when compared to that seen in ERα-
only cells (3252 ERα [αβ cells] vs. 4405 ERα [α cells] ChIP-chip sites). In contrast, the number 
of ERβ sites assessed by ChIP-chip are not constricted by ERα (1744 ERβ [αβ cells] vs. 1897 
ERβ [β cells] ChIP-chip sites). Comparing with the ChIP-seq data (see Table 4.2), we observe 
the restriction of ERα binding sites by ERβ (19950 ERα [αβ cells] vs. 37898 ERα [α cells] ChIP-
seq sites), which is in agreement with the ChIP-chip study. However, ERβ binding sites are also 
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restricted by ERα in our ChIP-seq study (20288 ERβ [αβ cells] vs. 37757 ERβ [β cells] ChIP-seq 
sites). The restriction of ERβ was not seen in our ChIP-chip study. It is possible that the 
difference between the two studies is due to a lack of a number of ERβ binding sites that were 
detected by the custom-designed NimbleGen array (ChIP-chip study). As the NimbleGen array 
was designed using known ERα sites, binding sites unique to ERβ would not have been detected, 
whereas ChIP-seq is able to detect most of the ERβ binding sites. Therefore, the ChIP-chip study 
might not present a complete picture of ERβ binding in the genome, leading us to not detect the 
constriction of ERβ binding sites by ERα. 
Second, the ChIP-chip study indicated that ERα and ERβ are in competition for binding sites, 
with ERα “driving” ERβ to occupy sites less enriched in ER motif. Similarly, we also observed 
the dominant nature of ERα in our ChIP-seq study. In cells containing both ERs, we found that 
only 9% of sites unique to ERβ have an ER motif (Table 4.3D). This is in contrast to other ER 
sites which generally have 14-24% enrichment of ER motif (Table 4.3A, 4.3B, 4.3C, and 4.3E). 
Therefore, the shunting of ERβ by ERα to sites less enriched in ER motifs is also observed in the 
ChIP-seq data.  
As shown, despite the differences in technology, the ER binding site datasets generated by 
ChIP-seq are in good agreement with the earlier ChIP-chip data, because we are able to observe 
both the restriction of ER sites and the occupancy of sites less enriched in ER motifs by ERβ in 
the ChIP-seq data. 
 
4.4.5 ERα, But Not ERβ, has Enriched GATA and FOXA1 Motifs 
To determine whether there are any differences in the genomic sequences to which ERα and 
ERβ bind, we scanned the ERs sites for enriched motifs using MotifEnrich (Ken Sung 
unpublished data). Not surprisingly, our search revealed the ER response element as the topmost 
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overrepresented motif and identified several other motifs that had been found in previous studies 
[28, 31], such as BACH2, AP-1, SP-1 etc (Table 4.4 to Table 4.7). However, a comparison of the 
enriched motifs found near ERα [α cells] and ERβ [β cells] binding sites revealed a surprising 
result – both FOXA1 and GATA were overrepresented in ERα sites but not in ERβ sites (see 
Table 4.3). This is rather unexpected, as studies [26, 27, 47, 48] have shown that FOXA1 and 
GATA3 are E2-regulated genes, and both factors are crucial for ERα chromatin binding and 
subsequent activation of its target genes. In order to address the issue that some of the sites 
bound by GATA3 and FOXA1 might not contain conserved motifs recognizable by TRANSFAC 
PWMs, we analyzed the overlap of ERα [α cells] and ERβ [β cells] binding sites with the 
recently published FOXA1 ChIP-chip data [47] and the ChIP-seq data for FOXA1 and GATA3 
(GIS unpublished data, SayLi KONG, Guoliang Li and Edison Liu). We were therefore 
expecting ERβ to utilize either FOXA1 or GATA3 as cofactors. We found that both FOXA1 (p-
value < 1e-257) and GATA3 (p-value < 5e-313) binding sites have a higher propensity to 
overlap ERα [α cells] binding sites as compared to ERβ [β cells] binding sites (see Figure 4.4A-
4.4C). For example, using the GIS FOXA1 and GATA3 data, we found that 20.4% of ERα 
binding sites and 11.3% of ERβ binding sites have FOXA1 binding in close proximity (Figure 
4.4B) and 30.8% of ERα binding sites and 13.8% of ERβ binding sites have GATA3 binding in 
close proximity (Figure 4.4C). The result is even more striking if we separate ERα [α cells] and 
ERβ [β cells] sites into ERα-only [α cells], ERβ-only [β cells], and sites in common to both ERs 
(i.e., can be occupied by either ERα or ERβ when they are present alone) (see Figure 4.5A for 
the Venn separation diagram). Only ~3% of sites which are exclusively occupied by ERβ are co-
occupied by either FOXA1 or GATA3. In contrast, 18.6% to 33.9% of the sites exclusively 
bound by ERα are co-occupied by either FOXA1 or GATA3. (see Figure 4.6A-4.5C).  
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We then turned our attention at ER binding sites in [αβ cells], and we separated ERα [αβ 
cells] and ERβ [αβ cells] binding sites into sites where ERα binds uniquely (ERα-only[αβ 
cells]), ERβ binds uniquely (ERβ-only[αβ cells], and sites that can be shared by both ERs (ERα 
[αβ cells]&ERβ[αβ cells]) (see Figure 4.5B for the Venn separation diagram). We again 
observed that FOXA1 (p-value < 2e-70) and GATA3 (p-value < 2e-160) are recruited more 
frequently to ERα sites than to ERβ sites (see Figure 4.7A-4.7C). Overall, our genome-wide 
location analyses suggest the cofactors FOXA1 and GATA3 do not co-occupy ERβ binding sites 
as frequently as ERα binding sites. 
 
4.4.6 E2F Motif is Associated with ERβ Binding 
Although the E2F motif was overrepresented both in the binding sequences of ERα [α cells] 
and ERβ [β cells], we observed that E2F is three times more enriched in ERβ [β cells] compared 
to ERα [α cells] binding sites (see Table 4.8A). By plotting the occurrences of the E2F motif 
around ER binding sites, we observed that the E2F motif is more likely to be located on ERβ [β 
cells] peaks as compared to ERα [α cells] peaks (Figure 4.8A). We were therefore interested to 
know whether a similar distribution of E2F motif enrichment occurs across ERs binding sites in 
[αβ cells]. We again separated the binding sites into ERα-only[αβ cells], ERβ-only[αβ cells], and 
sites that can be shared by both ERs, and we analyzed these three ER binding site sets for 
enriched E2F motifs (see Table 4.8B and Figure 4.8B). Interestingly, we were not able to find 
any enrichment of E2F motif around the sites occupied by ERα-only[αβ cells], whereas a strong 
enrichment of E2F motif is observed in sites occupied by ERβ-only[αβ cells], suggesting that the 
E2F family of transcription factors might be recruited more frequently to ERβ sites.  It is 
possible that our motif scanning did not reveal the full extent of E2F binding in the genome as (i) 
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E2F can binds to imperfect E2F motifs, (ii) the TRANSFAC motif for E2F is unable to predict 
all the members of E2F binding, or (iii) the conservative p-value cutoff (p-value<1e-4) from our 
motif scanning program limits the number of E2F sites called. Hence, despite our results here, it 
is still conceivable that the E2F family members can be recruited by both ERs.  
The E2F family members consist of activators and repressors, with E2F1-E2F3a generally 
thought of as transcription activators and E2F3b-E2F8 as transcription repressors. It is possible 
that ERα and ERβ are recruiting different members of the E2F family, thus leading to the 
different transcription regulation programs that are observed between the two ERs in breast 
cancer cells. More detailed studies are required to distinguish the recruitment of members of E2F 
family by either ER. Nonetheless, the fact that our genome-wide analysis of ERs binding sites 
revealed enrichment of E2F motif around ERβ sites raises the possibility that E2F and ERβ 
might share a significant fraction of their cis-regulatory sites. 
 
4.4.7 ERβ is Occupying “Less Accessible” Sites   
MotifEnrich scanning indicates that 14-24% of the ERs binding sites contain the ERE motif 
(see Table 4.3), but interestingly, only 9% of the sites at ERβ-only [αβ cells] have an ERE motif 
(see Table 4.3D). This is consistent with what we saw previously [28], where ERβ sites are 
found to be shunted to sites less enriched in ERE motifs in the presence of ERα. Nucleosome 
depletion has been reported around transcription factor binding sites [49, 50], and it has been 
suggested that nucleosome depletion assists in directing transcription factors to bind to 
appropriate regulatory sites. Considering our observations that DNA sequences at ERβ sites are 
less enriched in GATA3 and FOXA1 motifs together with the fact that ERβ-only [αβ cells] are 
shunted to sites less enriched in ERE motif, we hypothesized that ERβ, in general, might be 
occupying less favorable or less accessible chromatin sites as compared to ERα. Therefore, we 
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applied intrinsic nucleosome preference model proposed by Kaplan and colleagues [51] to 
estimate nucleosome occupancy at ERα and ERβ sites. For comparison, we also looked at the 
intrinsic nucleosome occupancy of FOXA1 sites defined by ChIP-chip study [47]. Kaplan and 
colleagues first measured the genome-wide occupancy of nucleosomes assembled on purified 
yeast genomic DNA. Using this data, they devised a computational model, the intrinsic 
nucleosome preference model, which predicts nucleosome occupancy solely based on the DNA 
sequence. Therefore, by using the nuclesome preference model as proposed by Kaplan, we 
should be able predict the intrinsic nucleosome occupancy across ERα and ERβ binding sites. 
Using this model, we found that ERα sites (both in [α cells] and [αβ cells]) are more depleted of 
intrinsic nucleosomes as compared to ERβ sites (in [β cells] and [αβ cells]) (see Figure 4.9). This 
indicates that, in MCF-7 cells, ERα is binding to more accessible DNA sequences (ones with 
fewer intrinsic nucleosomes) as compared to ERβ. 
 
4.4.8 The Hierarchy of ERs Chromatin Binding Sites 
Upon binding to chromatin, ERα and ERβ will recruit coregulators to form a complex that is 
competent to effect transcription of the target genes. To characterize the transcriptional pathways 
among ERs and its coregulators, we assessed the chromatin recruitment of two of ER’s 
coregulators, SRC3 and RIP140, in MCF-7 cells that contain ERα separately, ERβ separately or 
both ERs, in response to E2 treatment (Methods, Table 4.9). SRC3, which is a member of the 
p160 family, is a classic coactivator of several nuclear hormone receptors including ERs [22]. 
RIP140 [13] is another nuclear hormone coregulator and has been shown to interact with ERα 
and modulate estrogen-induced gene activity [52, 53]. Since SRC3 and RIP140 are non-DNA 
binding coregulators that are recruited by ERs, we therefore expected that SRC and RIP140 
recruitment to chromatin would be dependent on ERs. Figure 4.10 shows that within each of the 
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MCF-7 sub-lines, most of the SRC3 and RIP140 sites are co-localized with ER binding sites. 
There does not seem to be a bias in recruiting SRC3 or RIP140 by either of the ERs. 
As there are more ER binding sites in the genome as compared to E2 regulated genes, we 
hypothesized that there is a hierarchy to ER chromatin binding sites, ranging from sites that are 
required for gene regulation to redundant sites. ER-mediated transcription can be thought of as a 
two-step process. First, upon activation by ligands, ERs searches for and binds to the regulatory 
regions of their target genes. Then, after binding to DNA, coregulators are recruited by the ERs 
to carry out all the subsequent biochemical reactions required for induction or repression of the 
genes. Because the transcriptional potency of the ERs depends on coregulator recruitment, ER 
genomic binding sites where both ER and coregulators are localized should represent the “most 
functional” sites of the ER chromatin binding sites. Identifying these sites should enable us to 
pinpoint important genes occupying the driver seats of ERs actions. We therefore sought to 
identify ER target genes through the overlap of E2-regulated genes with the genomic localization 
of the ERs and the coregulators SRC3 and RIP140. This should allow us to identify a set of high 
confidence ER direct target genes which we can use to understand and elucidate the gene 
regulatory functions of the ERs and the mechanisms behind the opposing roles that appear to be 
played by ERα and ERβ in breast cancer. 
 
4.4.9 SRC3 and RIP140 are Recruited to E2-Induced Genes by ERs 
We first segregated ERs sites into four categories (see Table 4.10): ER that co-localized on 
chromatin with both SRC3 and RIP140 (E+S+R), ER that co-localized on chromatin with either 
SRC3 or RIP140 (E+S and E+R, respectively), and ER sites that do not have co-localized SRC3 
or RIP140 (E). We then proceeded to define ER target genes using the different ER binding sites 
categories. Specifically, we classified ERs target genes as E2-regulated genes whose regulatory 
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regions (20kbp up- and down-stream of TSS) are bound by ERs and/or coregulators (sites from 
E+S+R, E+S, E+R, and E). The result (see Table 4.11) is especially striking as there is a strong 
bias for genes that are occupied by ER and its coregulators (genes bound to E+S+R, E+S, and 
E+R sites) to be E2 induced. The correlation between ER and coregulators occupancy with gene 
induction was the most pronounced at sites where ERs are bound together with SRC3 and 
RIP140 (genes with E+S+R sites). Collectively, our results suggest that ERs are quite capable of 
recruiting SRC3 and RIP140 to E2-induced genes, whereas SRC3 and RIP140 are seldom 
recruited by ERs to E2 repressed genes. 
SRC3 has been shown to promote the transcriptional activity of ERα [22, 23], and its 
depletion leads to the reduction of estrogen-stimulated proliferation of MCF-7 cells [24, 25]. 
RIP140 appears to be an atypical coregulator, as published data indicates that it can act either as 
a coactivator [13, 17, 19] or corepressor [20, 21]. It is therefore interesting to see that on a 
genome-wide scale, RIP140, despite its potential to act as a corepressor, is acting in concert with 
the coactivator SRC3 to positively regulate ER-mediated gene transcription in breast cancer 
cells. 
 
4.4.10 The ERs Together with SRC3 and RIP140 Define the ER-Mediated Transcriptional 
Program 
Several studies done by us and others have used breast cancer cells to examine ERα- and 
ERβ-mediated gene expression programs [3, 4, 8-10, 29]. To date, a myriad of biological 
processes ranging from cell-cell signaling, ion homeostasis, proliferation, control of cell cycle to 
apoptosis have been associated with genes regulated by ERs. However, no studies have 
heretofore convincingly identified genes that can explain ERα proliferative and ERβ anti-
proliferative actions in breast cancer cells.  To test the hypothesis that genes identified by us 
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(genes with E+S+R, E+S, and E+R binding sites, Table 4.11) represent important ER target 
genes, we interrogated these sets of genes for overrepresented gene ontology (GO) biological 
processes. We focused our analysis on genes from [α cells] and [β cells] as these genes should be 
directly targeted by ERα and ERβ, respectively, as the other ER subtype is not present together 
in the cell. As both SRC3 and RIP140 appeared to be acting in a cooperative manner with the 
ERs in enhancing gene regulation, we therefore combined genes from categories E+S+R, E+S 
and E+R (Table 4.11) into a single set for our GO analysis. Among the genes that are associated 
with sites occupied by ERα and its coregulators in [α cells], the GO terms “Regulation of cell 
proliferation” (GO 0042127) followed by “Positive regulation of cell proliferation” (GO 
0008284) were the most overrepresented (Table 4.12A) GO terms. It is noteworthy that the most 
enriched GO biological function in the set of ERα direct target genes is cell proliferation. This 
suggests that the main ERα-mediated regulatory pathway in breast cancer cells may be through 
the positive regulation of cell proliferation. 
In contrast, “Regulation of apoptosis” (GO 0042981), “Regulation of programmed cell 
death” (GO 0043067), “Regulation of cell death” (GO 0010941), “Positive regulation of 
apoptosis” (GO 0043065), “Positive regulation of programmed cell death” (GO 0043068), 
and “Positive regulation of cell death” (GO 0010942) dominated the GO list for genes that are 
associated with sites occupied by ERβ and its coregulators in [β cells] (Table 4.12B). The 
identification of apoptosis as the most enriched GO biological term in ERβ target genes suggests 
that the phenotypic consequences of ERβ-mediated transcriptional activity are in direct 
competition with those of ERα. The results presented here are complementary to those of our 
earlier GO analysis using genes uniquely regulated by ERs (section 4.4.2). Based on our 
combinatorial expression and binding sites analysis, we put forth the hypothesis that the 
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differences between the ERα- and ERβ-mediated activities observed in breast cancer cell are the 
consequence of the opposing groups of genes regulated by ERα and ERβ: ERα is inducing cell 
proliferative genes to effect its tumorigenic activity, whereas ERβ anti-proliferative activity is 
obtained by the up regulation of apoptotic genes. Our earlier analysis identified the down-
regulation of pro-apoptotic genes by ERα and the up-regulation of pro-apoptotic genes by ERβ, 
changes that enforce our conclusion here. 
 
4.5 DISCUSSION 
In this study, we report the genome-wide identification of ERα, ERβ, and coregulators SRC3, 
and RIP140 chromatin localization in multiple sub-lines of MCF-7 breast cancer cells, 
expressing various complements of ERα and ERβ, in the presence of E2. In addition, we carried 
out microarray expression profiling experiments to investigate the gene regulatory effects of ERα 
and ERβ in breast cancer cells in the presence of E2 and ER-subtype selective ligands. We 
generated a compendium of 10 genome-wide ChIP-seq datasets and a set of paired gene 
expression data which we used to dissect the complex transcriptional programs orchestrated by 
both ERα and ERβ in breast cancer cells. By analyzing the genome-wide localization data of 
ERα, ERβ, SRC3, and RIP140 with global gene expression, we were able to make several novel 
observations. 
First, we showed that FOXA1 and GATA3 are not as frequently co-occupied at ERβ 
chromatin binding sites compared to ERα chromatin binding sites. In contrast, we found the E2F 
motif to be highly enriched in ERβ but not ERα binding sites. Both FOXA1 and GATA3 are 
important DNA-bound cofactors of ERα [26, 27, 47, 48], and they have been shown to be 
necessary for ERα chromatin binding and subsequent activation of its target genes. The E2F 
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family members consist of activators and repressors, and the fact that our results show that ERβ 
binding sites are more enriched with E2F motifs raises the possibility that ERβ might be 
preferentially binding to the chromatin near E2F binding sites and utilizing some of the E2F 
members to affect the regulation of its target genes. In this regard, despite the fact that both ERα 
and ERβ have similar DNA-binding domains and thus can recognize the same estrogen response 
element motif on the DNA [54-57], our data suggests that there are other cofactors such as 
FOXA1, GATA3, E2F, etc, enforcing the selectivity and range of ERα and ERβ binding. 
Second, using the intrinsic nucleosome preference model proposed by Kaplan et al. [51], we 
showed that ERα is in general occupying chromatin sites that are more depleted of intrinsic 
nucleosomes compared to ERβ sites. This might, in part, explain why ERα has a more dominant 
presence in breast cancer cells, compared to ERβ, as it able to bind more easily to chromatin to 
regulate its target genes. This observation fits well with our previous study [28], where we 
proposed that ERα may be dominating ERβ in terms of binding to DNA. 
Third, by co-localizing ERs, SRC3 and RIP140 binding to gene expression, we found a 
strong bias for the recruitment of SRC3 and RIP140 by both ERα and ERβ to the regulatory 
regions of E2-induced genes. SRC3 recruitment by ERα to E2-induced genes was reported 
previously by others [30, 58]. It is interesting the RIP140, which can functions as either a 
coactivator or a corepressor, is acting in concert with SRC3 to induce gene transcription. Lanz et 
al. [58] has previously reported the association of corepressor proteins such as NURD, HDACs 
with SRC3 in E2-stimulated MCF-7 wild type cells. Studies have also shown that it is possible 
for corepressors to enhance transcription [59, 60]. It is therefore conceivable that a new 
unidentified role for SRC3 is its ability to activate transcription through the recruitment of 
corepressors in breast cancer cells. We also note that there is hardly any recruitment of SRC3 or 
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RIP140 to E2-repressed genes, which suggests that SRC3 and RIP140 are seldomly used by ER 
for gene repression in breast cancer cells. Our study has provided new insights into the 
underlying mechanism of ER-mediated transcriptional program, namely, that the SRC3-RIP140 
complex might be playing a central role in the induction of ER targeted genes in breast cancer 
cells. 
Finally, the co-localization of ERs, SRC3 and RIP140 binding to gene expression has 
allowed us to identify a set ERα and ERβ target genes. Various gene expression studies were 
done in an attempt to identify genes which can explain the divergent roles of ERα and ERβ in 
breast cancers. As yet, no studies have convincingly identified genes that can explain ERα 
proliferative and ERβ anti-proliferative actions, because all of the studies used the whole set of 
E2-stimulated genes and not the subset of ER-targeted genes. However, with our genome-wide 
location and expression analyses, we are able to filter the E2-stimulated genes and identify a core 
set of ER target genes. GO analysis showed that genes occupied by ERα, SRC3, and/or RIP140 
in [α cells] have the GO term of pro-proliferation as the most statistically enriched. Similarly, 
genes occupied by ERβ, SRC3, and/or RIP140 in [β cells] are statistically enriched with the GO 
term of pro-apoptotic. These sets of genes may, at least in part, be responsible for the distinct 
roles of ERα and ERβ in the regulation of breast cancer cell proliferation. 
In summary, our study has defined a complete list of ERα, ERβ, SRC3, and RIP140 
chromatin interaction sites in MCF-7 breast cancer cells and has delineated a network of 
interactions among these regulatory factors. Given the fact that the predominant hormone in 
breast cancer biology is E2, it is therefore important for us to understand the nature of its 
receptors - ERα and ERβ - in terms of their chromatin binding, their coregulator recruitment, and 
the subsequent regulation of ER-target genes. Coupled with paired gene expression data, we 
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were able to identify a core set of genes that correlate with ERα proliferative and ERβ anti-
proliferative effects. Our findings provide working models in which ERα-SRC3-RIP140-
mediated transcription plays a crucial role in breast cancer cell proliferation, whereas ERβ-
SRC3-RIP140-mediated transcription induces apoptosis in breast cancer.  
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4.6 TABLES AND FIGURES 
Table 4.1. List of cell cycle genes taken from [46]. These cell cycle genes were then correlated 
with [45] to identify proliferation genes. 
 
Genes Assigned cell cycle phase [46] Identified as breast tumors 
proliferation genes in [45]  
E2F5 G2/M  
CCNE1 G1/S Proliferation 
CCNE2 G1/S  
CDC25A G1/S  
MCM6 G1/S Proliferation 
SLBP G1/S  
NASP G1/S Proliferation 
TYMS S phase Proliferation 
BIRC5 G2/M Proliferation 
CDC25B G2/M Proliferation 
AURKA G2/M Proliferation 
TOP2A G2 Proliferation 
RRM2 S phase Proliferation 
BUB1B G2/M  
CCNB2 G2/M  
CENPA G2/M  
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Table 4.2. Summary of ER binding sites in the three MCF-7 cells expressing ERα only, both 
ERα and ERβ, or ERβ only. 
 
 [α cells] [αβ cells] [β cells] 
Total ERα binding sites 37898 19950 NA 
Total ERβ binding sites NA 20228 37757 
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Table 4.3. Evaluation of ER, FOXA1 and GATA motifs and their enrichment at ER binding 
sites. 
 
A. Enrichment of ER, FOXA1, and GATA motifs at ERα [α cells] binding sites 
TRANSFAC ID % of ERα [α cells] with motif p-value 
V_ER_Q6 14.31% 0 
V_HNF3ALPHA_Q6 1.53% 4.91E-91 
V_GATA1_05 2.19% 1.04E-139 
 
 
B. Enrichment of ER, FOXA1, and GATA motifs at ERβ [β cells] binding sites 
 TRANSFAC_PWM % of ERβ [β cells] with motif p-value 
V_ER_Q6_02 16.36% 0 
V_HNF3ALPHA_Q6 0.00% 1.00E+00 
V_GATA1_05 0.08% 2.36E-01 
 
 
C. Enrichment of ER, FOXA1, and GATA motifs at ERα-only [αβ cells] binding sites 
TRANSFAC_PWM % of ERα-only [αβ cells] with motif p-value 
V_ER_Q6 23.94% 0 
V_HNF3ALPHA_Q6 0.71% 2.37E-15 
V_GATA1_05 1.17% 1.29E-25 
 
 
D. Enrichment of ER, FOXA1, and GATA motifs at ERβ-only [αβ cells] binding sites 
TRANSFAC_PWM % of ERβ-only [αβ cells] with motif p-value 
V_ER_Q6_02 8.86% 0 
V_HNF3ALPHA_Q6 0.00% 1.00E+00 
V_GATA1_05 0.00% 1.00E+00 
 
 
E. Enrichment of ER, FOXA1, and GATA motifs at ERα [αβ cells] & ERβ[αβ cells] binding 
sites 
TRANSFAC_PWM 
% of ERα [αβ cells] & ERβ [αβ cells] 
with motif p-value 
V_ER_Q6 22.28% 0 
V_HNF3ALPHA_Q6 0.00% 1.00E+00 
V_GATA1_05 0.28% 8.07E-05 
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Table 4.4. TFBS enrichment in ERα[α cells] binding sites. 
Rank 
Motif 
Family Transfac ID 
% of sites with 
motif p-value 
1 ERE V_ER_Q6 14.31% 0 
2 BACH V_BACH2_01 5.56% 0 
3 AP1 V_AP1_01 5.54% 0 
4 AP2 V_AP2ALPHA_02 4.61% 0 
5 FOX V_FREAC4_01 4.38% 0 
6 CREB V_ATF3_Q6 3.05% 0 
7 NRF V_NRF2_Q4 2.95% 0 
8 AR V_AR_01 2.88% 0 
9 DBP V_DBP_Q6 2.80% 0 
10 GATA V_GATA_Q6 2.51% 4.87E-152 
11 MEF3 V_MEF3_B 2.31% 4.12E-157 
12 NF1 V_NF1_Q6 1.98% 1.97E-105 
13 LMAF V_LMAF_Q2 1.97% 2.06E-123 
14 VMAF V_VMAF_01 1.88% 1.61E-110 
15 FXR V_PXR_Q2 1.70% 1.96E-76 
16 LRH1 V_LRH1_Q5 1.69% 1.97E-68 
17 PAX V_PAX6_Q2 1.56% 3.37E-96 
18 EBOX V_USF_Q6_01 1.55% 2.71E-85 
19 HIC1 V_HIC1_03 1.46% 3.77E-73 
20 MYOGNF1 V_MYOGNF1_01 1.33% 1.43E-69 
21 MAF V_MAF_Q6_01 1.29% 1.43E-67 
22 SMAD V_SMAD4_Q6 1.22% 2.31E-65 
23 SP1 V_SP1_Q6_01 1.20% 4.22E-51 
24 CACCC V_CACCCBINDINGFACTOR_Q6 1.07% 2.69E-47 
25 MYB V_MYB_Q6 1.06% 1.05E-47 
26 ETS V_NERF_Q2 1% 2.24E-45 
27 
GATA 
DIMER V_EVI1_06 1% 4.37E-45 
28 CP2 V_CP2_01 0.94% 6.06E-41 
29 AP4 V_AP4_Q6_01 0.92% 2.47E-38 
30 TEF V_TEF1_Q6 0.91% 3.93E-13 
31 MEIS1 V_MEIS1_01 0.90% 7.90E-35 
32 CMAF V_CMAF_01 0.90% 3.05E-26 
33 ROAZ V_ROAZ_01 0.85% 5.82E-39 
34 P53 V_P53_02 0.78% 2.98E-36 
35 MIF1 V_MIF1_01 0.75% 3.35E-37 
36 HEN V_LBP1_Q6 0.72% 1.19E-24 
37 E2F V_E2F1_Q4 0.70% 9.09E-35 
38 TGTGGT V_PEBP_Q6 0.68% 9.90E-27 
39 KAISO V_KAISO_01 0.67% 3.22E-28 
40 OLF1 V_OLF1_01 0.64% 6.87E-27 
41 TGIF V_TGIF_01 0.55% 2.73E-18 
42 STAT V_STAT1_01 0.55% 1.62E-26 
43 PTF1BETA V_PTF1BETA_Q6 0.53% 5.79E-18 
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Table 4.4. (cont.) 
Rank 
Motif 
Family Transfac ID 
% of sites with 
motif p-value 
44 EGR V_EGR1_01 0.48% 3.43E-20 
45 SOX V_SOX10_Q6 0.47% 3.22E-07 
46 NFKB V_NFKAPPAB65_01 0.47% 7.03E-18 
47 RFX V_RFX1_01 0.46% 5.11E-14 
48 XPF1 V_XPF1_Q6 0.45% 2.14E-40 
49 SP3 V_SP3_Q3 0.44% 1.44E-24 
50 EBF V_EBF_Q6 0.38% 5.99E-17 
51 IK V_IK3_01 0.37% 1.29E-13 
52 SEF1 V_SEF1_C 0.37% 4.64E-17 
53 DEAF1 V_DEAF1_01 0.35% 4.27E-22 
54 XVENT1 V_XVENT1_01 0.34% 1.70E-12 
55 P300 V_P300_01 0.32% 7.17E-18 
56 CEBP V_CEBP_01 0.31% 1.91E-06 
57 CACCT V_AREB6_01 0.30% 3.78E-15 
58 ZF5 V_ZF5_B 0.29% 1.87E-21 
59 LEF V_LEF1_Q2_01 0.16% 0.000524 
60 E2 V_E2_Q6 0.15% 3.78E-08 
61 TATA V_MTATA_B 0.13% 2.26E-06 
62 MINI V_MINI19_B 0.12% 4.42E-14 
63 LDSPOLYA V_LDSPOLYA_B 0.12% 9.41E-05 
64 ALX4 V_ALX4_01 0.12% 1.68E-06 
65 CAAT V_YY1_02 0.11% 1.05E-06 
66 WHN V_WHN_B 0.10% 1.53E-12 
67 SREB V_SREBP_Q3 0.09% 0.000516 
68 Initiator V_GEN_INI3_B 0.07% 1.94E-07 
69 AHR V_AHR_01 0.06% 0.120647 
70 IPF V_IPF1_Q4 0.06% 0.000105 
71 ZEC V_ZEC_01 0.04% 0.124365 
72 HOX V_HOXA7_01 0.03% 0.000182 
73 BRACH V_TBX5_02 0.03% 0.044359 
74 GCM V_GCM_Q2 0.01% 7.30E-05 
75 OCT V_OCT1_06 0.01% 0.037178 
76 GGG V_CHCH_01 0% 1.21E-05 
 
 
We used MotifEnrich to scan for enriched motifs in ERα[α cells] binding sites. The motifs are 
ranked according to their enrichment (descending order) in ERα[α cells] binding sites. 
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Table 4.5. TFBS enrichment in ERα[αβ cells] binding sites. 
 
Rank 
Motif 
Family Transfac 
% of sites with 
motif p-value 
1 ERE V_ER_Q6 23.05% 0 
2 CREB V_ATF3_Q6 4.23% 0 
3 AP1 V_AP1_Q6 4.17% 0 
4 BACH V_BACH2_01 4.08% 0 
5 AR V_AR_01 3.48% 1.65E-137 
6 AP2 V_AP2ALPHA_02 3.47% 0 
7 NRF V_NRF2_Q4 3.01% 2.01E-140 
8 NF1 V_NF1_Q6 2.96% 8.26E-146 
9 EBOX V_USF_Q6_01 2.84% 6.20E-121 
10 VMAF V_VMAF_01 2.41% 3.45E-101 
11 MEF3 V_MEF3_B 2.38% 6.56E-95 
12 PAX V_PAX6_Q2 2.33% 2.13E-92 
13 LMAF V_LMAF_Q2 2.22% 4.71E-90 
14 LRH1 V_LRH1_Q5 2.08% 1.51E-60 
15 MYOGNF1 V_MYOGNF1_01 1.65% 3.20E-48 
16 FXR V_PXR_Q2 1.61% 3.00E-59 
17 HIC1 V_HIC1_02 1.51% 1.41E-48 
18 FOX V_FREAC4_01 1.49% 5.06E-41 
19 SP1 V_SP1_01 1.49% 2.58E-61 
20 SMAD V_SMAD4_Q6 1.41% 1.40E-46 
21 MAF V_MAF_Q6_01 1.40% 2.26E-64 
22 AP4 V_AP4_Q6 1.33% 3.31E-40 
23 DBP V_DBP_Q6 1.30% 3.59E-28 
24 ROAZ V_ROAZ_01 1.16% 7.54E-39 
25 MEIS1 V_MEIS1_01 0.94% 1.21E-26 
26 E2F V_E2F_Q4_01 0.88% 1.31E-28 
27 HEN V_LBP1_Q6 0.85% 2.79E-25 
28 MIF1 V_MIF1_01 0.82% 3.15E-28 
29 MYB V_MYB_Q6 0.75% 1.17E-16 
30 P53 V_P53_DECAMER_Q2 0.72% 3.30E-21 
31 TGTGGT V_PEBP_Q6 0.72% 1.59E-20 
32 CACCC V_CACCCBINDING_Q6 0.72% 9.66E-20 
33 GATA V_GATA1_05 0.71% 8.54E-12 
34 CP2 V_CP2_02 0.68% 4.04E-38 
35 SEF1 V_SEF1_C 0.63% 4.65E-14 
36 SP3 V_SP3_Q3 0.56% 2.28E-23 
37 ETS V_CETS1P54_01 0.55% 5.51E-20 
38 TGIF V_TGIF_01 0.54% 1.77E-12 
39 CMAF V_CMAF_01 0.50% 4.34E-13 
40 DEAF1 V_DEAF1_01 0.50% 8.08E-20 
41 STAT V_STAT1_01 0.47% 2.14E-18 
42 DEC V_DEC_Q1 0.46% 3.18E-12 
43 OLF1 V_OLF1_01 0.44% 2.82E-17 
44 TEF V_TEF1_Q6 0.42% 0.041814963 
45 ZF5 V_ZF5_B 0.41% 5.71E-18 
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Table 4.5. (cont.) 
Rank 
Motif 
Family Transfac 
% of sites with 
motif p-value 
46 RFX V_RFX1_01 0.39% 4.19E-13 
47 KAISO V_KAISO_01 0.38% 2.87E-12 
48 XPF1 V_XPF1_Q6 0.36% 4.70E-21 
49 PTF1BETA V_PTF1BETA_Q6 0.36% 5.06E-08 
50 MINI V_MINI19_B 0.31% 3.23E-18 
51 EGR V_EGR1_01 0.31% 1.30E-13 
52 HES V_HES1_Q2 0.30% 1.25E-12 
53 E2 V_E2_01 0.29% 3.03E-17 
54 SREB V_SREBP_Q3 0.28% 6.50E-14 
55 CAAT V_YY1_02 0.26% 2.15E-14 
56 GLI V_ZIC3_01 0.26% 7.60E-15 
57 SOX V_SOX10_Q6 0.22% 1.46E-06 
58 NANOG V_NANOG_01 0.20% 4.48E-09 
59 BRACH V_TBX5_02 0.20% 6.29E-06 
60 EBF V_EBF_Q6 0.18% 1.08E-10 
61 MTF1 V_MTF1_Q4 0.17% 2.89E-08 
62 P300 V_P300_01 0.17% 2.98E-10 
63 NFKB V_NFMUE1_Q6 0.15% 2.20E-09 
64 CACCT V_AREB6_01 0.14% 1.87E-10 
65 WT1 V_WT1_Q6 0.13% 2.11E-09 
66 IK V_IK1_01 0.06% 1.17E-08 
67 R V_R_01 0.06% 1.68E-05 
68 ZBRK1 V_ZBRK1_01 0.06% 1.77E-06 
69 
GATA 
DIMER V_EVI1_06 0.03% 0.002920699 
70 AHR V_AHR_01 0% 0.000133724 
 
 
We used MotifEnrich to scan for enriched motifs in ERα[αβ cells] binding sites. The motifs are 
ranked according to their enrichment (descending order) in ERα[αβ cells] binding sites. 
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Table 4.6. TFBS enrichment in ERβ[αβ cells] binding sites. 
 
Rank 
Motif 
Family Transfac ID 
% of sites with 
motif p-value 
1 ERE V_ER_Q6_02 16.80% 0 
2 AP1 V_AP1_01 4.91% 0 
3 BACH V_BACH2_01 4.88% 0 
4 CREB V_ATF3_Q6 4.26% 0 
5 EBOX V_USF_Q6_01 3.84% 0 
6 AP2 V_AP2ALPHA_01 3.64% 0 
7 SP1 V_SP1_01 3.51% 0 
8 E2F V_E2F_Q6_01 3.41% 8.42E-128 
9 NRF V_NRF2_Q4 3.37% 0 
10 HIC1 V_HIC1_02 3.30% 0 
11 AR V_AR_01 3.18% 3.08E-152 
12 ZF5 V_ZF5_B 2.91% 4.78E-133 
13 NF1 V_NF1_Q6 2.67% 1.59E-115 
14 EGR V_KROX_Q6 2.45% 1.34E-89 
15 DEAF1 V_DEAF1_01 2.31% 6.97E-90 
16 VMAF V_VMAF_01 2.27% 3.54E-77 
17 PAX V_PAX5_01 2.25% 6.59E-103 
18 LMAF V_LMAF_Q2 2.21% 3.53E-93 
19 MEF3 V_MEF3_B 2.21% 2.47E-81 
20 ETS V_GABP_B 2.12% 9.77E-72 
21 LRH1 V_LRH1_Q5 2.04% 2.12E-62 
22 SMAD V_SMAD4_Q6 1.97% 1.89E-78 
23 MOVO V_MOVOB_01 1.77% 8.29E-67 
24 MYOGNF1 V_MYOGNF1_01 1.70% 1.19E-53 
25 ROAZ V_ROAZ_01 1.67% 2.84E-64 
26 MINI V_MINI19_B 1.61% 5.16E-58 
27 HEN V_HEN1_02 1.61% 6.67E-62 
28 MAF V_MAF_Q6_01 1.53% 7.60E-61 
29 FXR V_PXR_Q2 1.46% 1.25E-51 
30 AP4 V_AP4_Q6 1.44% 1.15E-52 
31 MIF1 V_MIF1_01 1.34% 4.29E-45 
32 CP2 V_CP2_02 1.34% 1.16E-49 
33 CACCC V_CACCCBINDING_Q6 1.18% 3.81E-37 
34 AHR V_AHRARNT_02 1.16% 1.23E-41 
35 WT1 V_WT1_Q6 1.05% 2.00E-37 
36 GGG V_CHCH_01 1% 1.54E-35 
37 OLF1 V_OLF1_01 0.95% 1.32E-30 
38 MEIS1 V_MEIS1_01 0.87% 4.32E-26 
39 WHN V_WHN_B 0.84% 7.76E-32 
40 STAT V_STAT1_01 0.83% 3.87E-32 
41 MYB V_CMYB_01 0.83% 2.54E-30 
42 SP3 V_SP3_Q3 0.79% 1.23E-32 
43 HES V_HES1_Q2 0.79% 5.66E-28 
44 NFKB V_NFKAPPAB50_01 0.76% 4.21E-27 
45 P53 V_P53_01 0.72% 7.43E-16 
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Table 4.6. (cont.) 
Rank 
Motif 
Family Transfac ID 
% of sites with 
motif p-value 
46 E2 V_E2_Q6 0.72% 5.03E-28 
47 RFX V_RFX1_01 0.64% 2.78E-17 
48 DBP V_DBP_Q6 0.62% 3.38E-11 
49 MTF1 V_MTF1_Q4 0.55% 7.08E-23 
50 FOX V_FREAC4_01 0.54% 1.47E-08 
51 TGTGGT V_PEBP_Q6 0.53% 4.93E-15 
52 GLI V_ZIC3_01 0.51% 4.46E-16 
53 R V_R_01 0.50% 1.41E-17 
54 DEC V_DEC_Q1 0.48% 1.30E-15 
55 ZNF219 V_ZNF219_01 0.43% 7.52E-22 
56 CMAF V_CMAF_01 0.43% 1.96E-12 
57 P300 V_P300_01 0.38% 8.54E-16 
58 VMYB V_VMYB_02 0.38% 8.79E-15 
59 KAISO V_KAISO_01 0.36% 1.11E-16 
60 XPF1 V_XPF1_Q6 0.33% 2.70E-13 
61 CAAT V_NFY_01 0.30% 7.37E-08 
62 SREB V_SREBP_Q3 0.28% 4.87E-12 
63 PTF1BETA V_PTF1BETA_Q6 0.26% 1.12E-09 
64 NANOG V_NANOG_01 0.26% 6.91E-11 
65 TGIF V_TGIF_01 0.23% 5.46E-10 
66 ZBRK1 V_ZBRK1_01 0.23% 1.86E-10 
67 ZID V_ZID_01 0.22% 1.39E-12 
68 EBF V_EBF_Q6 0.20% 2.72E-12 
69 GCM V_GCM_Q2 0.19% 1.23E-10 
70 LRF V_LRF_Q2 0.18% 5.55E-14 
71 CACCT V_AREB6_01 0.12% 1.47E-09 
72 SPZ V_SPZ1_01 0.09% 5.83E-13 
73 SEF1 V_SEF1_C 0.08% 3.34E-06 
74 TFIII V_TFIII_Q6 0.07% 3.32E-11 
75 SOX V_SOX10_Q6 0.04% 0.016002141 
76 BRACH V_TBX5_02 0.03% 0.0002267 
77 HMX1 V_HMX1_01 0.01% 2.27E-08 
78 STAF V_STAF_01 0% 1.06E-05 
 
 
We used MotifEnrich to scan for enriched motifs in ERβ[αβ cells] binding sites. The motifs are 
ranked according to their enrichment (descending order) in ERβ[αβ cells] binding sites. 
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Table 4.7. TFBS enrichment in ERβ[β cells] binding sites. 
  
Rank 
Motif 
Family Transfac ID 
% of sites with 
motif p-value 
1 ERE V_ER_Q6_02 16.36% 0 
2 AP1 V_AP1_Q6 4.53% 0 
3 BACH V_BACH2_01 4.36% 0 
4 CREB V_ATF3_Q6 4.19% 0 
5 AP2 V_AP2ALPHA_02 3.91% 0 
6 EBOX V_USF_Q6_01 3.66% 0 
7 AR V_AR_01 3.37% 0 
8 NRF V_NRF2_Q4 3.05% 0 
9 LMAF V_LMAF_Q2 2.58% 0 
10 HIC1 V_HIC1_02 2.50% 0 
11 LRH1 V_LRH1_Q5 2.42% 2.80E-156 
12 NF1 V_NF1_Q6 2.36% 0 
13 MEF3 V_MEF3_B 2.36% 0 
14 PAX V_PAX6_Q2 2.27% 5.18E-114 
15 VMAF V_VMAF_01 2.11% 1.75E-114 
16 SP1 V_SP1_01 2.08% 5.19E-130 
17 SMAD V_SMAD4_Q6 2.07% 1.87E-124 
18 E2F V_E2F_Q4_01 1.84% 1.57E-91 
19 FXR V_PXR_Q2 1.83% 1.08E-128 
20 MYOGNF1 V_MYOGNF1_01 1.64% 1.15E-82 
21 ROAZ V_ROAZ_01 1.56% 5.78E-91 
22 DEAF1 V_DEAF1_01 1.53% 6.24E-80 
23 MAF V_MAF_Q6_01 1.49% 9.43E-96 
24 HEN V_HEN1_02 1.49% 2.47E-85 
25 ZF5 V_ZF5_B 1.44% 4.03E-66 
26 AP4 V_AP4_Q5 1.36% 8.55E-89 
27 CP2 V_CP2_02 1.35% 1.50E-75 
28 MIF1 V_MIF1_01 1.34% 6.54E-66 
29 MEIS1 V_MEIS1_01 1.29% 3.04E-60 
30 CACCC V_CACCCFACTOR_Q6 1.25% 2.63E-62 
31 ETS V_NERF_Q2 1.21% 7.12E-73 
32 EGR V_EGR3_01 1.14% 2.56E-51 
33 MYB V_CMYB_01 1.12% 2.03E-49 
34 MINI V_MINI19_B 1.12% 4.75E-59 
35 P53 V_P53_02 1.06% 3.99E-54 
36 DBP V_DBP_Q6 1.01% 1.16E-30 
37 FOX V_FREAC4_01 1% 2.02E-27 
38 SP3 V_SP3_Q3 0.91% 1.67E-47 
39 OLF1 V_OLF1_01 0.80% 2.81E-40 
40 HES V_HES1_Q2 0.77% 5.87E-41 
41 EBF V_EBF_Q6 0.76% 7.60E-36 
42 STAT V_STAT1_01 0.73% 1.36E-39 
43 TGIF V_TGIF_01 0.71% 6.60E-19 
44 TGTGGT V_PEBP_Q6 0.69% 1.24E-25 
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Table 4.7. (cont.) 
Rank 
Motif 
Family Transfac ID 
% of sites with 
motif p-value 
45 WT1 V_WT1_Q6 0.58% 1.85E-28 
46 MOVO V_MOVOB_01 0.58% 1.84E-34 
47 AHR V_AHRARNT_02 0.56% 3.71E-26 
48 MTF1 V_MTF1_Q4 0.53% 1.96E-25 
49 E2 V_E2_01 0.53% 3.26E-37 
50 CMAF V_CMAF_01 0.53% 7.60E-14 
51 XPF1 V_XPF1_Q6 0.52% 6.37E-19 
52 NFKB V_NFKAPPAB50_01 0.52% 3.44E-24 
53 WHN V_WHN_B 0.52% 4.15E-29 
54 RFX V_RFX1_01 0.51% 6.71E-22 
55 GGG V_CHCH_01 0.48% 5.86E-26 
56 P300 V_P300_01 0.45% 2.18E-28 
57 PTF1BETA V_PTF1BETA_Q6 0.43% 1.13E-14 
58 DEC V_DEC_Q1 0.43% 1.95E-21 
59 CAAT V_YY1_02 0.40% 3.78E-20 
60 CACCT V_AREB6_01 0.37% 6.42E-18 
61 BRACH V_TBX5_02 0.37% 9.35E-14 
62 GLI V_ZIC3_01 0.36% 9.58E-31 
63 SREB V_SREBP_Q3 0.35% 1.70E-18 
64 KAISO V_KAISO_01 0.35% 1.63E-22 
65 SEF1 V_SEF1_C 0.32% 1.33E-12 
66 R V_R_01 0.31% 7.79E-19 
67 ZBRK1 V_ZBRK1_01 0.29% 6.01E-13 
68 ZNF219 V_ZNF219_01 0.22% 2.83E-20 
69 ZID V_ZID_01 0.22% 6.31E-16 
70 NANOG V_NANOG_01 0.18% 8.59E-15 
71 IK V_IK1_01 0.18% 1.56E-08 
72 TFIII V_TFIII_Q6 0.15% 1.68E-09 
73 VMYB V_VMYB_02 0.15% 3.45E-11 
74 TEF V_TEF1_Q6 0.13% 0.871926 
75 GATA V_GATA1_05 0.08% 0.23605 
76 GCM V_GCM_Q2 0.08% 2.32E-12 
77 SZF11 V_SZF11_01 0.06% 0.001904 
78 HMX1 V_HMX1_01 0.04% 7.01E-10 
79 SOX V_SOX10_Q6 0.01% 0.147899 
80 IPF V_IPF1_Q4_01 0.01% 0.00013 
 
We used MotifEnrich to scan for enriched motifs in ERβ[β cells] binding sites. The motifs are 
ranked according to their enrichment (descending order) in ERβ[β cells] binding sites.
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 Table 4.8. Evaluation of E2F motifs and their enrichment at ER binding sites. 
 
A. Enrichment of E2F motif at ERα [α cells] and ERβ [β cells] binding sites 
ER binding sites % of ER sites with E2F motif p-value 
ERα [α cells] 0.51% 1.54E-33 
ERβ [β cells] 1.74% 6.90E-87 
 
 
B. Enrichment of E2F motif at ERα and ERβ binding sites in [αβ cells] 
ER binding sites % of ER sites with E2F motif p-value 
ERα-only [αβ cells] 0% 1 
ERβ-only [αβ cells] 6.89% 8.25E-160 
ERα [αβ cells] & ERβ [αβ 
cells] 0.85% 3.29E-25 
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Table 4.9. Summary of SRC3 and RIP140 chromatin affinity sites in the three MCF-7 cells 
expressing ERα only, both ERα and ERβ, or ERβ only. 
 
 [α cells] [αβ cells] [β cells] 
Total SRC3 binding sites 4030 6833 6056 
Total RIP140 binding sites 2119 2513 8924 
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Table 4.12. Analysis for enriched biological processes in ERα and ERβ target genes. 
 
A. 10 most enriched biological processes terms of ERα [α cells] targeted genes 
 
 
 
 
 
 
 
 
 
 
B. 10 most enriched biological processes terms of ERβ [β cells] targeted genes 
 
 
 
 
 
 
 
 
 
 
DAVID analysis for enriched biological processes terms of genes whose regulatory regions are 
bound by ERα with SRC3 and RIP140 in [α cells] and genes that are regulatory regions are 
bound by ERβ with SRC3 and RIP140 in [β cells]. Top 10 most enriched biological processes 
terms as identified by DAVID are shown. 
 
Rank Term Count PValue Fold Enrichment
1 GO:0042127~regulation of cell proliferation 16 0.001799943 2.460670194
2 GO:0008284~positive regulation of cell proliferation 10 0.006605061 2.937049942
3 GO:0006357~regulation of transcription from RNA polymerase II promoter 13 0.014552865 2.183330013
4 GO:0050678~regulation of epithelial cell proliferation 4 0.019138314 6.980814355
5 GO:0010629~negative regulation of gene expression 10 0.021120574 2.422918463
6 GO:0016055~Wnt receptor signaling pathway 5 0.022851186 4.596146856
7 GO:0032553~ribonucleotide binding 25 0.023905015 1.554364865
8 GO:0032555~purine ribonucleotide binding 25 0.023905015 1.554364865
9 GO:0030695~GTPase regulator activity 9 0.024941106 2.528695854
10 GO:0045892~negative regulation of transcription, DNA-dependent 8 0.025639154 2.744593678
Rank Term Count PValue Fold Enrichment
1 GO:0042981~regulation of apoptosis 40 9.98E-06 2.130358963
2 GO:0043067~regulation of programmed cell death 40 1.25E-05 2.1091085
3 GO:0010941~regulation of cell death 40 1.38E-05 2.101248468
4 GO:0033273~response to vitamin 9 1.52E-04 5.766494375
5 GO:0043065~positive regulation of apoptosis 24 1.84E-04 2.388007082
6 GO:0012501~programmed cell death 30 1.90E-04 2.117911123
7 GO:0043068~positive regulation of programmed cell death 24 2.05E-04 2.371268715
8 GO:0010942~positive regulation of cell death 24 2.19E-04 2.360239558
9 GO:0006915~apoptosis 29 3.36E-04 2.0785443
10 GO:0033189~response to vitamin A 7 4.18E-04 7.04793757
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Figure 4.1. Gene Regulation in MCF-7 Cells Containing Various Complements of ERα and 
ERβ. (A) Percentage of up- and down- regulated genes upon E2 treatment in cells expressing 
ERα alone, ERα and ERβ, and ERβ alone. (B) Percentage of up- and down- regulated genes 
upon ER sub-type selective ligands treatment in cells expressing ERα alone, ERα and ERβ, and 
ERβ alone. PPT is an ERα selective ligand whereas ERB-041 only activates ERβ. 
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Figure 4.2. Global Analysis of Cellular Processes Regulated Uniquely by ERα and ERβ. (A) 
Venn diagram showing the subsets of E2-regulated genes used for GO analysis. Only genes that 
are uniquely regulated in each cell-type were selected. (B) In the ERα-only cluster, we observed 
that most of the genes with enriched GO term of “Apoptosis” and “Transcription repressor 
activity” are E2-repressed. (C) Genes with enriched GO term of “Programmed cell death” and 
“Response to DNA damage” are mostly E2-induced in the ERβ-only cluster. 
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Figure 4.2. (cont.) 
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Figure 4.3. Gene expression profiles of cell cycle and proliferation genes. The 19 cell cycle and 
proliferation genes were examined for their E2-incuded expression in the microarray data. (A) 
Genes are down-modulated by ERβ (comparing expression to ERα cells) in the presence of ERα 
(B) Genes up-regulated by ERα and ERβ. 
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Figure 4.4. Genome-wide analysis of FOXA1 and GATA3 binding sites with ERα[α cells] and 
ERβ[β cells] binding sites. We analyzed the overlap of ERα[α cells] and ERβ[β cells] binding 
sites for FOXA1 binding sites and GATA3 binding sites. (A) We overlapped ERα[α cells] and 
ERβ[β cells] binding sites with FOXA1 ChIP-chip binding sites [47]. (B) ERα[α cells] and 
ERβ[β cells] binding sites were overlapped with FOXA1 ChIP-seq binding sites (GIS 
unpublished data, Edison Liu). (C) ERα[α cells] and ERβ[β cells] binding sites were overlapped 
with GATA3 ChIP-seq binding sites (GIS unpublished data, Edison Liu).  
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Figure 4.4. (cont.) 
 
 
 106
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. Venn diagrams showing the overlap of ER binding sites when they are present either 
separately or together in MCF-7 cells. (A) Overlap of ERα [α cells] with ERβ [β cells] binding 
sites. (B) Overlap of ERα [αb cells] with ERβ [αβ cells] binding sites. 
ERα[α cells] ERβ[β cells] 
ERα−only[α cells]  ERβ−only[β cells] 
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Figure 4.6. Genome-wide analysis of FOXA1 and GATA3 binding sites with ERα[α cells] and 
ERβ[β cells] binding sites. ERα [α cells] and ERβ [β cells] binding sites are separated into ERα-
only [α cells], ERβ-only [β cells], and sites in common to both ERs (ERα[α cells]&ERβ[β 
cells]). These ER sites are then reanalyzed for overlap with FOXA1 and GATA3 binding. (A) 
Overlap of ERs binding sites with FOXA1 ChIP-chip binding sites [47]. (B) ERs binding sites 
were overlapped with FOXA1 ChIP-seq binding sites (GIS unpublished data, Edison Liu). (C) 
ERs binding sites were overlapped with GATA3 ChIP-seq binding sites (GIS unpublished data, 
Edison Liu).    
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Figure 4.6. (cont.) 
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Figure 4.7. Genome-wide analysis of FOXA1 and GATA3 binding sites with ERα[αβ cells] and 
ERβ[αβ cells] binding sites. ERα [αβ cells] and ERβ [αβ cells] binding sites are separated to 
sites where ERα can uniquely binds (ERα-only[αβ cells]), ERβ can uniquely binds (ERβ-
only[αβ cells], and where both ER can binds (ERα [αβ cells]&ERβ[αβ cells]). FOXA1 and 
GATA3 binding site are then overlapped with these sites. (A) Overlap of ERs binding sites with 
FOXA1 ChIP-chip binding sites [47]. (B) ERs binding sites were overlapped with FOXA1 ChIP-
seq binding sites (GIS unpublished data, Edison Liu). (C) ERs binding sites were overlapped 
with GATA3 ChIP-seq binding sites (GIS unpublished data, Edison Liu).    
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Figure 4.7. (cont.) 
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Figure 4.8. Histograms of the occurrences of E2F motif. The frequency of occurrences of the 
E2F motif centered on ER binding sites is plotted. We extend the region to 5000bp up- and 
down-stream of the ER peak. (A) E2F motif occurrences around ERα [α cells] binding sites and 
ERβ [β cells] binding sites. (B) E2F motif occurrences around ERα-only binding sites, ERβ-only 
binding sites, and ERα & ERβ binding sites in [αβ cells]. 
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Figure 4.9. Intrinsic Nucleosome Occupancy across ER sites. We used the intrinsic nucleosome 
preference model (proposed by Kaplan et al. [51]) to estimate nucleosome occupancy at ERα and 
ERβ sites. As reference, we also considered the nucleosome occupancy of FOXA1 sites. A score 
of 1 will indicate full intrinsic nucleosome occupancy whereas a score of 0 will indicate 
nucleosome free region. 
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Figure 4.10. Co-localization of ER binding sites with SRC3 and RIP140. We overlapped SRC3 
and RIP140 ChIP-seq data to ER binding sites in each of the respective cell-type (in [α cells], 
[αβ cells], and [β cells]). The majority of SRC3 and RIP140 are co-localized with ER binding 
sites and they are recruited equally well by both ERα and ERβ. 
 
 
0
20
40
60
80
100
S
R
C
3[
α]
R
IP
14
0[
α]
SR
C
3[
αβ
]
R
IP
14
0[
αβ
]
SR
C
3[
αβ
]
R
IP
14
0[
αβ
]
S
R
C
3[
β]
R
IP
14
0[
β]
ERα[α cells] ERα[αβ cells] ERβ[αβ cells] ERβ[β cells]%
 o
f c
or
eg
ul
at
or
 s
ite
s 
bo
un
d 
by
 E
R
 114
4.7 REFERENCES 
1. Deroo, B.J. and K.S. Korach, Estrogen receptors and human disease. J Clin Invest, 2006. 
116(3): p. 561-70. 
2. Nilsson, S., et al., Mechanisms of estrogen action. Physiol Rev, 2001. 81(4): p. 1535-65. 
3. Frasor, J., et al., Profiling of estrogen up- and down-regulated gene expression in human 
breast cancer cells: insights into gene networks and pathways underlying estrogenic 
control of proliferation and cell phenotype. Endocrinology, 2003. 144(10): p. 4562-74. 
4. Chang, E.C., et al., Estrogen Receptors alpha and beta as determinants of gene 
expression: influence of ligand, dose, and chromatin binding. Mol Endocrinol, 2008. 
22(5): p. 1032-43. 
5. Lazennec, G., et al., ER beta inhibits proliferation and invasion of breast cancer cells. 
Endocrinology, 2001. 142(9): p. 4120-30. 
6. Paruthiyil, S., et al., Estrogen receptor beta inhibits human breast cancer cell 
proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res, 2004. 
64(1): p. 423-8. 
7. Strom, A., et al., Estrogen receptor beta inhibits 17beta-estradiol-stimulated 
proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci U S A, 2004. 
101(6): p. 1566-71. 
8. Williams, C., et al., A genome-wide study of the repressive effects of estrogen receptor 
beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene, 2008. 27(7): 
p. 1019-32. 
9. Lin, C.Y., et al., Inhibitory effects of estrogen receptor beta on specific hormone-
responsive gene expression and association with disease outcome in primary breast 
cancer. Breast Cancer Res, 2007. 9(2): p. R25. 
10. Chang, E.C., et al., Impact of estrogen receptor beta on gene networks regulated by 
estrogen receptor alpha in breast cancer cells. Endocrinology, 2006. 147(10): p. 4831-
42. 
11. Glass, C.K. and M.G. Rosenfeld, The coregulator exchange in transcriptional functions 
of nuclear receptors. Genes Dev, 2000. 14(2): p. 121-41. 
12. McKenna, N.J. and B.W. O'Malley, Combinatorial control of gene expression by nuclear 
receptors and coregulators. Cell, 2002. 108(4): p. 465-74. 
13. Cavailles, V., et al., Nuclear factor RIP140 modulates transcriptional activation by the 
estrogen receptor. Embo J, 1995. 14(15): p. 3741-51. 
14. Carascossa, S., et al., Receptor-interacting protein 140 is a repressor of the androgen 
receptor activity. Mol Endocrinol, 2006. 20(7): p. 1506-18. 
15. Subramaniam, N., E. Treuter, and S. Okret, Receptor interacting protein RIP140 inhibits 
both positive and negative gene regulation by glucocorticoids. J Biol Chem, 1999. 
274(25): p. 18121-7. 
16. Masuyama, H., et al., Evidence for ligand-dependent intramolecular folding of the AF-2 
domain in vitamin D receptor-activated transcription and coactivator interaction. Mol 
Endocrinol, 1997. 11(10): p. 1507-17. 
17. Nephew, K.P., et al., Studies of dehydroepiandrosterone (DHEA) with the human 
estrogen receptor in yeast. Mol Cell Endocrinol, 1998. 143(1-2): p. 133-42. 
 115
18. Sheeler, C.Q., M.W. Dudley, and S.A. Khan, Environmental estrogens induce 
transcriptionally active estrogen receptor dimers in yeast: activity potentiated by the 
coactivator RIP140. Environ Health Perspect, 2000. 108(2): p. 97-103. 
19. Henttu, P.M., E. Kalkhoven, and M.G. Parker, AF-2 activity and recruitment of steroid 
receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in 
nuclear receptors. Mol Cell Biol, 1997. 17(4): p. 1832-9. 
20. Lee, C.H., C. Chinpaisal, and L.N. Wei, Cloning and characterization of mouse RIP140, 
a corepressor for nuclear orphan receptor TR2. Mol Cell Biol, 1998. 18(11): p. 6745-55. 
21. Christian, M., et al., RIP140-targeted repression of gene expression in adipocytes. Mol 
Cell Biol, 2005. 25(21): p. 9383-91. 
22. Anzick, S.L., et al., AIB1, a steroid receptor coactivator amplified in breast and ovarian 
cancer. Science, 1997. 277(5328): p. 965-8. 
23. Suen, C.S., et al., A transcriptional coactivator, steroid receptor coactivator-3, 
selectively augments steroid receptor transcriptional activity. J Biol Chem, 1998. 
273(42): p. 27645-53. 
24. Azorsa, D.O., H.E. Cunliffe, and P.S. Meltzer, Association of steroid receptor 
coactivator AIB1 with estrogen receptor-alpha in breast cancer cells. Breast Cancer Res 
Treat, 2001. 70(2): p. 89-101. 
25. Louie, M.C., et al., ACTR/AIB1 functions as an E2F1 coactivator to promote breast 
cancer cell proliferation and antiestrogen resistance. Mol Cell Biol, 2004. 24(12): p. 
5157-71. 
26. Carroll, J.S., et al., Chromosome-wide mapping of estrogen receptor binding reveals 
long-range regulation requiring the forkhead protein FoxA1. Cell, 2005. 122(1): p. 33-
43. 
27. Carroll, J.S., et al., Genome-wide analysis of estrogen receptor binding sites. Nat Genet, 
2006. 38(11): p. 1289-97. 
28. Charn, T.H., et al., Genome-wide dynamics of chromatin binding of estrogen receptors 
alpha and beta: mutual restriction and competitive site selection. Mol Endocrinol. 24(1): 
p. 47-59. 
29. Frasor, J., et al., Selective estrogen receptor modulators: discrimination of agonistic 
versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer 
Res, 2004. 64(4): p. 1522-33. 
30. Kininis, M., et al., Genomic analyses of transcription factor binding, histone acetylation, 
and gene expression reveal mechanistically distinct classes of estrogen-regulated 
promoters. Mol Cell Biol, 2007. 27(14): p. 5090-104. 
31. Lin, C.Y., et al., Whole-genome cartography of estrogen receptor alpha binding sites. 
PLoS Genet, 2007. 3(6): p. e87. 
32. Liu, Y., et al., The genome landscape of ERalpha- and ERbeta-binding DNA regions. 
Proc Natl Acad Sci U S A, 2008. 105(7): p. 2604-9. 
33. Frasor, J., et al., Gene expression preferentially regulated by tamoxifen in breast cancer 
cells and correlations with clinical outcome. Cancer Res, 2006. 66(14): p. 7334-40. 
34. Manas, E.S., et al., Structure-based design of estrogen receptor-beta selective ligands. J 
Am Chem Soc, 2004. 126(46): p. 15106-19. 
35. Stauffer, S.R., et al., Pyrazole ligands: structure-affinity/activity relationships and 
estrogen receptor-alpha-selective agonists. J Med Chem, 2000. 43(26): p. 4934-47. 
 116
36. Barnett, D.H., et al., Estrogen receptor regulation of carbonic anhydrase XII through a 
distal enhancer in breast cancer. Cancer Res, 2008. 68(9): p. 3505-15. 
37. Choi, I., et al., Human estrogen receptor beta-specific monoclonal antibodies: 
characterization and use in studies of estrogen receptor beta protein expression in 
reproductive tissues. Mol Cell Endocrinol, 2001. 181(1-2): p. 139-50. 
38. Zhang, Y., et al., Model-based analysis of ChIP-Seq (MACS). Genome Biol, 2008. 9(9): 
p. R137. 
39. Huang da, W., B.T. Sherman, and R.A. Lempicki, Systematic and integrative analysis of 
large gene lists using DAVID bioinformatics resources. Nat Protoc, 2009. 4(1): p. 44-57. 
40. Dennis, G., Jr., et al., DAVID: Database for Annotation, Visualization, and Integrated 
Discovery. Genome Biol, 2003. 4(5): p. P3. 
41. Malamas, M.S., et al., Design and synthesis of aryl diphenolic azoles as potent and 
selective estrogen receptor-beta ligands. J Med Chem, 2004. 47(21): p. 5021-40. 
42. Hartman, J., et al., Estrogen receptor beta inhibits angiogenesis and growth of T47D 
breast cancer xenografts. Cancer Res, 2006. 66(23): p. 11207-13. 
43. Bishop, J.M., Molecular themes in oncogenesis. Cell, 1991. 64(2): p. 235-48. 
44. Hunter, T., Oncoprotein networks. Cell, 1997. 88(3): p. 333-46. 
45. Perou, C.M., et al., Molecular portraits of human breast tumours. Nature, 2000. 
406(6797): p. 747-52. 
46. Whitfield, M.L., et al., Identification of genes periodically expressed in the human cell 
cycle and their expression in tumors. Mol Biol Cell, 2002. 13(6): p. 1977-2000. 
47. Lupien, M., et al., FoxA1 translates epigenetic signatures into enhancer-driven lineage-
specific transcription. Cell, 2008. 132(6): p. 958-70. 
48. Eeckhoute, J., et al., Positive cross-regulatory loop ties GATA-3 to estrogen receptor 
alpha expression in breast cancer. Cancer Res, 2007. 67(13): p. 6477-83. 
49. Albert, I., et al., Translational and rotational settings of H2A.Z nucleosomes across the 
Saccharomyces cerevisiae genome. Nature, 2007. 446(7135): p. 572-6. 
50. Lee, W., et al., A high-resolution atlas of nucleosome occupancy in yeast. Nat Genet, 
2007. 39(10): p. 1235-44. 
51. Kaplan, N., et al., The DNA-encoded nucleosome organization of a eukaryotic genome. 
Nature, 2009. 458(7236): p. 362-6. 
52. Augereau, P., et al., Transcriptional regulation of the human NRIP1/RIP140 gene by 
estrogen is modulated by dioxin signalling. Mol Pharmacol, 2006. 69(4): p. 1338-46. 
53. Teyssier, C., et al., Receptor-interacting protein 140 binds c-Jun and inhibits estradiol-
induced activator protein-1 activity by reversing glucocorticoid receptor-interacting 
protein 1 effect. Mol Endocrinol, 2003. 17(2): p. 287-99. 
54. Cowley, S.M., et al., Estrogen receptors alpha and beta form heterodimers on DNA. J 
Biol Chem, 1997. 272(32): p. 19858-62. 
55. Li, X., et al., Single-chain estrogen receptors (ERs) reveal that the ERalpha/beta 
heterodimer emulates functions of the ERalpha dimer in genomic estrogen signaling 
pathways. Mol Cell Biol, 2004. 24(17): p. 7681-94. 
56. Pace, P., et al., Human estrogen receptor beta binds DNA in a manner similar to and 
dimerizes with estrogen receptor alpha. J Biol Chem, 1997. 272(41): p. 25832-8. 
57. Pettersson, K., et al., Mouse estrogen receptor beta forms estrogen response element-
binding heterodimers with estrogen receptor alpha. Mol Endocrinol, 1997. 11(10): p. 
1486-96. 
 117
58. Lanz, R.B., et al., Global characterization of transcriptional impact of the SRC-3 
coregulator. Mol Endocrinol. 24(4): p. 859-72. 
59. Perissi, V., et al., A corepressor/coactivator exchange complex required for 
transcriptional activation by nuclear receptors and other regulated transcription factors. 
Cell, 2004. 116(4): p. 511-26. 
60. Peterson, T.J., et al., The silencing mediator of retinoic acid and thyroid hormone 
receptor (SMRT) corepressor is required for full estrogen receptor alpha transcriptional 
activity. Mol Cell Biol, 2007. 27(17): p. 5933-48. 
 
 
 118
CHAPTER 5 
CONCLUSION 
In this thesis report, I have systematically mapped the genomic landscape of ERα, ERβ, 
SRC3, and RIP140 in multiple sub-lines of MCF-7 breast cancer cells, expressing various 
complements of ERα and ERβ, in the presence of E2. In addition to the genome-wide binding 
site cartographies, we also carried out gene expression profiling analyses to investigate the gene 
regulatory effects of ERα and ERβ in breast cancer cells. We were able to reveal several 
important ERs biological mechanisms in breast cancer by analyzing the global cartographies of 
ERα, ERβ, SRC3, and RIP140 together with microarray expression profiling data. 
By analyzing ERα and ERβ chromatin binding sites, we found that ERα and ERβ bind to a 
similar, large number of sites in breast cancer cells containing only one ER subtype. However, in 
cells containing both ERα and ERβ, we observed that the two ERs appear to restrict each others 
chromatin binding and occupy fewer sites. This result suggests that, on a genome scale, there is 
active competition between the two receptors for chromatin binding sites when they are present 
together in cells, and they can no longer bind in an unobstructed manner to their native binding 
sites when they are present alone in the cells. Motifs enrichment analyses on ERα and ERβ 
binding sites suggest that, despite both ERs having highly conserved DNA-binding domain, there 
are differences in term of enriched motifs in the vicinity of ERα and ERβ binding sites. ERα 
binding sites are enriched in GATA and FOXA1 motifs, whereas ERβ sites are preferentially 
enriched in E2F motifs, suggesting that there are other cofactors such as FOXA1, GATA3, E2F, 
etc., enforcing the selectivity and range of ERα and ERβ binding. 
Analysis of ERα, ERβ, SRC3, and RIP140 ChIP-seq data revealed that the coregulators 
SRC3 and RIP140 are recruited preferentially by both ERα and ERβ to the regulatory regions of 
estrogen-induced genes. Interestingly, SRC3 or RIP140 are seldom recruited by ER to estrogen-
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repressed genes, which suggest that SRC3 and RIP140 are rarely used by ER for gene repression 
in breast cancer cells. Taken together, our study has provided new insight into the underlying 
mechanisms of ER-mediated transcriptional program, namely, that the SRC3-RIP140 complex 
might be playing a central role in the induction of ER target genes in breast cancer cells. 
Gene ontology analysis of our gene chip microarray transcriptional profiling data enabled us 
to delineate a core set of genes that correlate with ERα proliferative and ERβ anti-proliferative 
effects in breast cancer cells. We found that ERβ activation by estradiol was associated with the 
inhibition of genes associated with cell proliferation and the up-regulation of pro-apoptotic genes 
and genes responding to DNA damage, whereas ERα activation was associated with the 
downregulation of pro-apoptotic genes and genes repressing transcription. These sets of genes 
may, at least in part, be responsible for the distinct roles of ERα and ERβ in breast cancer cell 
proliferation. 
In summary, the data presented in this report has provided an integrated model in which the 
actions of cofactors such as FOXA1, GATA3, and E2F enforce the selectivity and range of ERα 
and ERβ binding and gene regulatory actions, with the coregulators SRC3 and RIP140 
preferentially supporting the stimulatory actions of both receptors on gene expression in breast 
cancer cells. Furthermore, the genome-wide cartographies of ERα and ERβ and coregulators, 
SRC3 and RIP140, and the ER target genes provided in this thesis report will be invaluable for 
the investigation of ER signaling in breast cancer. 
 
